U.S. patent application number 11/226351 was filed with the patent office on 2007-10-11 for bioreactor design and process for engineering tissue from cells.
This patent application is currently assigned to Univ. of North Carolina at Chapel Hill. Invention is credited to Jeffrey M. MacDonald, Stephen P. Wolfe.
Application Number | 20070238176 11/226351 |
Document ID | / |
Family ID | 35482491 |
Filed Date | 2007-10-11 |
United States Patent
Application |
20070238176 |
Kind Code |
A1 |
MacDonald; Jeffrey M. ; et
al. |
October 11, 2007 |
Bioreactor design and process for engineering tissue from cells
Abstract
A scaled-up multi-coaxial fiber bioreactor, and variations of
this bioreactor. The device is characterized by a hollow housing
and an array of from about 20 to about 400 modules of hollow
fibers, where each module includes at least three coaxial
semipermeable hollow fibers. The innermost fiber provides a
boundary for an innermost compartment which is connected to inlet
and outlet ports. Arranged coaxially around the central hollow
fiber are several other hollow fibers with their respective
compartments, each compartment defined by a respective annular
space between adjacent fibers and each including inlet and outlet
ports. An outermost compartment for permitting integral aeration is
the space between the outer side of the outermost fibers and the
inner side of the housing, and has inlet and outlet ports. The
hollow housing has inlet and outlet manifolds and flow distributors
for each of the compartments. In a preferred embodiment the
bioreactor is used as an extracorporeal liver. Liver cells, are
introduced into one or more annular compartments and media and
aeration are provided in others. Plasma from an ailing patient is
introduced into another compartment for biotransformation of
blood-borne toxins and biosynthesis of proteins, lipids, and other
metabolic products.
Inventors: |
MacDonald; Jeffrey M.;
(Chapel Hill, NC) ; Wolfe; Stephen P.; (Chapel
Hill, NC) |
Correspondence
Address: |
FOLEY AND LARDNER LLP;SUITE 500
3000 K STREET NW
WASHINGTON
DC
20007
US
|
Assignee: |
Univ. of North Carolina at Chapel
Hill
Chapel Hill
NC
|
Family ID: |
35482491 |
Appl. No.: |
11/226351 |
Filed: |
September 15, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09586981 |
Jun 5, 2000 |
6979308 |
|
|
11226351 |
Sep 15, 2005 |
|
|
|
60137594 |
Jun 3, 1999 |
|
|
|
Current U.S.
Class: |
435/395 |
Current CPC
Class: |
B01D 63/021 20130101;
B01D 63/02 20130101; C12M 29/16 20130101; C12M 25/14 20130101; B01D
63/022 20130101; C12M 23/34 20130101; B01D 63/026 20130101 |
Class at
Publication: |
435/395 |
International
Class: |
C12N 5/00 20060101
C12N005/00 |
Goverment Interests
[0002] Government Interests: This invention was made with support
under 1 F32 DK09713-01 awarded by the National Institute of
Diabetes, Digestive, and Kidney Diseases. The government has
certain rights in the invention.
Claims
1. A bioreactor, comprising: (a) a housing having an inner side
comprising: a gas introduction means integral to the housing; and a
gas expiration means integral to the housing; (b) an array of a
plurality of modules of hollow fibers, residing within the housing,
each module comprising: (i) a plurality of coaxial hollow fibers,
each having an inner side and an outer side, including an innermost
hollow fiber and an outermost hollow fiber; (ii) a plurality of
compartments, comprising: a first compartment defined by the inner
side of the innermost hollow fiber; and (iii) at least one
additional compartment defined by a respective annular space
between adjacent fibers of the plurality of coaxial hollow fibers;
and (c) an outermost compartment defined by a space within the
inner side of the housing which is not occupied by the plurality of
modules.
2. The bioreactor of claim 1, where the hollow fibers are
semipermeable.
3. The bioreactor of claim 2, where the hollow fibers comprise a
material selected from the group consisting of polysulfone,
polypropylene, nylon, polyester, polytetrafluoroethylene, cellulose
acetate, and mixed esters of cellulose.
4. The bioreactor of claim 1, where the first compartment, the at
least one additional compartment and the outermost compartment each
further comprise at least one inlet port and at least one outlet
port.
5. The bioreactor of claim 1, where the bioreactor further
comprises at least 10.sup.9 cells.
6. The bioreactor of claim 5, where the cells are liver cells.
7. The bioreactor of claim 6, where the liver cells are selected
from the group consisting of porcine liver cells and human liver
cells.
8. The bioreactor of claim 4, where the housing further comprises
at least one inlet manifold and at least one outlet manifold for
the first compartment and at least one inlet manifold and at least
one outlet manifold for each additional compartment.
9. The bioreactor of claim 8, where at least one manifold further
comprises a flow distributor.
10. The bioreactor of claim 9, where at least one compartment
further comprises an extracellular matrix.
11. The bioreactor of claim 1, where at least one annular space is
about 0.2 millimeters to about 0.8 millimeters.
12. The bioreactor of claim 1, where the bioreactor is sterilized
by a means selected from the group consisting of autoclaving,
ethylene oxide and gamma radiation.
13. The bioreactor of claim 1, wherein the innermost hollow fiber
has a length of about 2 centimeters to about 50 centimeters.
14. The bioreactor of claim 8, where the housing has a first end
and a second end, and where each inlet port and each exit port are
at the first end of the housing.
15. The bioreactor of claim 8, further comprising: microfibers
substantially parallel to the modules of hollow fibers.
16. The bioreactor of claim 15, where the microfibers further
comprise at least one aeration inlet port and at least one aeration
outlet port.
17. The bioreactor of claim 1, where at least one coaxial hollow
fiber is saturated with perfluorocarbon.
18. The bioreactor of claim 1, where at least one coaxial hollow
fiber has a pore size less than 1.times.10.sup.-6 m.
19. The bioreactor of claim 1, where at least one coaxial hollow
fiber has a pore size less than 0.1.times.10.sup.-6 m.
20. The bioreactor of claim 1, where at least one coaxial hollow
fiber has a pore size less than 0.05.times.10.sup.-6 m.
21. The bioreactor of claim 1, where at least one compartment
further comprises cells mixed with an extracellular matrix.
22. A method of supplying cell biosynthesis products to a patient
in need thereof, comprising: pumping intravenous feeding solution
through a compartment of the bioreactor of claim 5; collecting the
output; and intravenously feeding the output to the patient.
23. A serially-linked bioreactor, comprising a plurality of
bioreactor subunits, each bioreactor subunit comprising: (a) a
housing having an inner side comprising: a gas introduction means
integral to the housing; and a gas expiration means integral to the
housing; (b) an array of a plurality of modules of hollow fibers,
residing within the housing, each module comprising; (i) a
plurality of coaxial hollow fibers, each having an inner side and
an outer side, including an innermost hollow fiber and an outermost
hollow fiber; (ii) a plurality of compartments, comprising: a first
compartment defined by the inner side of the innermost hollow
fiber; and at least one additional compartment defined by a
respective annular space between adjacent fibers of the plurality
of coaxial hollow fibers; and (c) an outermost compartment, defined
by a space within the inner side of the housing which is not
occupied by the plurality of modules; and (d) at least one
compartment of one bioreactor subunit linked serially to at least
one compartment of at least one other bioreactor subunit.
24. The bioreactor of claim 23, where each bioreactor subunit
further comprises at least 10.sup.9 cells.
25. The bioreactor of claim 24, where the cells are liver
cells.
26. The bioreactor of claim 25 where the cells are selected from
the group consisting of human liver cells and porcine liver
cells.
27. The bioreactor of claim 24, where at least one compartment of
each bioreactor subunit further comprises an extracellular
matrix.
28. A method of treating a patient in need thereof comprising: (a)
introducing plasma of a patient into a bioreactor subunit of the
serially linked bioreactor of claim 23, (b) forcing at least a
portion of the plasma to flow radially through a cell compartment
of the bioreactor subunit to form a biotransformed effluent; (c)
introducing the biotransformed effluent into a second bioreactor
subunit of the bioreactor of claim 23; (d) forcing at least a
portion of the biotransformed effluent to flow radially through a
cell compartment of the second bioreactor subunit to form
supplemented plasma; and (e) returning the supplemented plasma to
the patient's circulatory system.
29. A multi-coaxial hollow fiber bioreactor, comprising: (a) a
housing comprising an inner side; and (b) a module of hollow
fibers, comprising: at least three coaxial semipermeable hollow
fibers, including an innermost fiber having an inner side, the
inner side defining a first compartment which comprises at least
one innermost inlet port and at least one innermost outlet port; a
plurality of compartments, each compartment defined by a respective
annular space between adjacent fibers of the at least three hollow
fibers, including at least one outer inlet port and at least one
outer outlet port, where each compartment comprises a flow
communication means between the respective annular space, the
respective outer inlet port and the respective outer outlet port
and where one of the annular spaces contains eucaryotic cells; and
(c) an outermost compartment defined by a space between the outer
side of the outermost fiber of said at least three hollow fibers,
and the inner side of the housing, and comprising at least one
outermost inlet port, and at least one outermost outlet port; the
housing comprising at least one inlet manifold and at least one
outlet manifold for each of the compartments; where at least one of
the compartments contains eucaryotic cells.
30. A method of cell culture, comprising: introducing viable cells
into a compartment of the bioreactor of claim 29, and passing
nutrient medium through coaxially adjacent hollow fibers.
31. A method of manufacture of a coaxial bioreactor, comprising:
(a) bonding outer semipermeable hollow fibers to a manifold, (b)
inserting middle semipermeable hollow fibers into the outer
semipermeable hollow fibers, (c) bonding the middle semipermeable
hollow fibers to a second manifold, (d) inserting the inner
semipermeable hollow fibers into the middle semipermeable hollow
fibers, and (e) bonding the inner semipermeable hollow fibers to a
third manifold.
32. The method of claim 31 where inserting middle semipermeable
hollow fibers into the outer semipermeable hollow fibers is
vacuum-assisted.
33. The method of claim 31 where inserting inner semipermeable
hollow fibers into the middle semipermeable hollow fibers is vacuum
assisted.
34. An apparatus for assembly of a bioreactor, comprising: (a) a
vacuum head, attached to a negative pressure source, the vacuum
head comprising: a hollow housing; a mesh to retain hollow fibers,
where the mesh is affixed to the housing; and a holder for a
manifold; (b) a vessel for holding polyurethane epoxy and ends of
hollow fibers.
35. A device for maintaining viable eucaryotic cells, comprising:
(a) an annular compartment, having an annular space, (b) two
compartments, adjacent and coaxial to said annular space, where
each adjacent compartment contains a liquid, and (c) an integral
aeration supply for the annular space.
36. The device of claim 35, in which the annular space is about 0.2
to about 0.8 mm.
37. The device of claim 35, additionally comprising a second
annular compartment having a second annular space.
38. A method of treating a patient in need thereof, the device
comprising: (a) circulating plasma from a patient into a device,
comprising: (i) an annular compartment, having an annular space and
a complement of eukaryotic cells therein, (ii) at least two
compartments, adjacent and coaxial to said annular space, where
each adjacent compartment contains a liquid, (iii) an integral
aeration supply for the annular space; and (b) allowing a portion
of the plasma to traverse the annular compartment.
39. The method of claim 38, in which the said traversing is
facilitated by pressure.
40. The method of claim 38, where said portion of the plasma is
returned to the patient's circulation system.
41. The method of claim 38, in which said device additionally
comprises a second annular compartment having a second annular
space and a complement of eukaryotic cells therein.
42. The method of claim 39, in which said device additionally
comprises a second annular compartment having a second annular
space and a complement of eukaryotic cells therein.
43. The method of claim 40, in which said device additionally
comprises a second annular compartment having a second annular
space and a complement of eukaryotic cells therein.
44. The method of claim 42, in which said portion of the plasma is
returned to the patient's circulation system.
45. A method of selecting a radial flow rate to enhance cell
viability in a bioreactor comprising semi-permeable fibers,
comprising: measuring a first hydraulic pressure associated with a
first semi-permeable fiber and a second hydraulic pressure
associated with a second semi-permeable fiber to obtain a pressure
differential and adjusting the first hydraulic pressure, the second
hydraulic pressure, or a combination thereof to select one or more
radial flow rates so as to improve cell viability.
46. The method of claim 45 in which the first fiber and the second
fiber are coaxial.
47. The method of claim 46 in which the radial flow rate is
selected based on the formula: .DELTA. .times. .times. P = Q 2
.times. .pi. .times. .times. L [ ln .function. ( r b r a ) K 1 - ln
.function. ( r d r c ) K 2 ] ##EQU3## where .DELTA.P is the
pressure differential, Q is the radial flow rate, L is the length
of the shorter of the first and second fiber lengths, r.sub.a is
the radial distance from the centerline of the bioreactor to the
inner surface of the first fiber, r.sub.b is the radial distance
from the centerline of the bioreactor to the outer surface of the
first fiber, r.sub.c is the radial distance from the centerline of
the bioreactor to the inner surface of the second fiber, r.sub.d is
the radial distance from the centerline of the bioreactor to the
outer surface of the second fiber, K.sub.1 is the hydraulic
permeability of the first fiber, and K.sub.2 is the hydraulic
permeability of the second fiber.
48. A computer readable medium including instructions therein for
calculating a radial flow rate in a bioreactor comprising
semi-permeable fibers, said instructions including the steps of:
(a) receiving measurements of hydraulic permeability for each of at
least two coaxial semi-permeable fibers, (b) receiving measurements
of hydraulic pressure for at least two coaxial semi-permeable
fibers, and (c) estimating said radial flow rate between said
coaxial semi-permeable fibers.
Description
[0001] This application claims priority to U.S. Provisional
Application No. 60/137,594, filed Jun. 3, 1999, the complete
disclosure of which is incorporated by reference herein.
1. FIELD OF THE INVENTION
[0003] The present invention relates generally to devices and
processes of making and using devices for cell culture. In
particular, the present invention relates to devices and processes
of making and using devices for growth or maintenance of eukaryotic
cells. One embodiment of the invention performs functions of the
human liver.
2. BACKGROUND OF THE INVENTION AND RECOGNITION OF THE PROBLEMS
[0004] Liver failure is classified into several major types,
including acute liver failure, chronic liver disease, and
multiorgan failure. The main etiologies of liver failure are viral
hepatitis and hepatotoxicity induced by drugs and toxins. Advanced
liver failure results in encephalopathy and coma, and may be fatal.
Treatment focuses on stabilization of the patient until spontaneous
recovery of liver function, or until liver transplantation. In the
aggregate, the annual mortality attributable to liver failure
exceeds 27,000 annually in the United States.
[0005] Artificial organs, which are devices made entirely of
non-biological materials, have greatly advanced health care.
Artificial organs and tissue substitutes, including kidney dialysis
machines, mechanical respirators, cardiac pacemakers, and
mechanical heart pumps have sustained many people with desperate
life-threatening diseases. The utility of such artificial organs is
reflected in their widespread use. Pacemakers, for example, serve
admirably as substitutes for their biological analogs.
[0006] The artificial kidney, sometimes termed the kidney dialysis
machine, illustrates both the benefits and shortcomings of purely
artificial organs. Kidney dialysis machines are effective in
removing urea, creatinine, water, and excess salts from the blood,
thus partly fulfilling major roles of the natural kidney. Clearly,
artificial kidneys have postponed deaths of patients in renal
failure. However, kidney dialysis machines are insufficiently
selective and inappropriately remove biological components, such as
steroid hormones, that a functioning natural kidney does not.
Consequently, dialysis over an extended period may result in bone
loss, clotting irregularities, immunodeficiencies, and
sterility.
[0007] The patient in hepatic failure, unlike the patient in renal
failure, cannot be specifically treated. Renal dialysis, which
revolutionized the treatment of renal failure, does not presently
have a hepatic equivalent. Currently, the only available treatment
for refractory liver failure is hepatic transplantation. Many
patients in hepatic failure do not qualify for transplantation
because of concomitant infection, or other organ failure. Because
of organ shortages and long waiting lists, even those who qualify
for liver transplantation often die while awaiting an allograft.
UCLA reported that one quarter of their transplant candidates died
before a liver could be obtained. Organs suitable for transplant in
the pediatric age group are even more scarce (Busuttil, R. W. et
al. Ann Surg 1987,206, 387).
[0008] The natural liver has four major classes of biochemical
functions. First, the liver biosynthesizes a wide range of
proteins, including major acellular components of blood, such as
serum albumin, alpha-anti-trypsin, alpha-macroglobulin, enzymes,
clotting factors, carrier molecules for trace elements, and the
apo-lipoproteins. The liver then releases these components to the
blood circulation. The liver also maintains appropriate plasma
concentrations of amino and fatty acids. Second, the liver has a
major role in detoxification reactions. The liver oxidizes or
conjugates many harmful external poisons, processes that usually,
but not always, diminish the poisonous character of the toxins. The
liver also destroys excess hemoglobin, metabolizes the porphyrin
molecules of hemoglobin, and recycles the iron component. Third,
waste products, such as bilirubin, are conjugated and excreted via
the biliary tree. Fourth, the liver synthesizes and secretes the
bile salts, which serve as detergents that promote the
emulsification and digestion of lipids. The multiplicity and
biochemical character of liver function vastly increase the
complexity of extracorporeal hepatic support.
[0009] Bioartificial organs are artificial organs designed to
contain and sustain a viable biological component. Many biological
functions are even more complex than simply generating a voltage
potential at regular intervals, as occurs in the simplest of
pacemakers. Examples include biosynthesis of blood components and
catabolic processing of deleterious agents. The liver, endocrine
glands, bone marrow, and kidney are prominent in such specialized
biochemical functions. Artificial organs without a biological
component cannot reproduce the complex biochemical functions
executed by these organs.
[0010] Historically, non-biologic artificial liver substitutes have
depended on hemodialysis and hemoperfusion, but have been of very
short-term and highly limited benefit (Abe, T. et al., Therapeutic
Apheresis 2000, 4:26). In contrast to purely artificial organs, an
effective liver replacement must have a biological component. The
liver is the most massive organ in the human body, exclusive of
distributed organs such as skin, gut, hematopoietic system, and
vasculature. Sustaining a large mass of functioning liver cells in
vitro presents a variety of hurdles. At least eight major problems
to developing a functional bioartificial liver can be described: 1)
growing or obtaining appropriate and viable cells; 2) providing for
a critical minimum mass of cells; 3) supplying oxygen to the cells;
4) supplying nutrients to the cells, and removing cell waste
products efficiently; 5) limiting shear forces and hydrostatic
pressures, 6) inducing or sustaining a differentiated cell
phenotype with the capacity for biosynthesis and biotransformation
of toxins; 7) maintaining sterility; and 8) preventing liver tissue
rejection or lysis by complement.
[0011] 1) Growing or obtaining appropriate and viable cells. Liver
cells for potential use in bioartificial livers can be established
cell lines, primary isolates from human or animal livers, or
primordial liver cells however, secretion of tumorigenic factors is
negatively affecting FDA approval of BAL designs incorporating cell
lines (Xu, A. S. L. et al., 2000 in Lineage Biology and Liver,
Lanza, R. P., Langer R., and Vacanti, J. (Ed.), Academic Press, San
Diego, pp. 559-597). Cell lines of liver are available, for example
HepG2 and C3A, that express many functions of differentiated liver.
Cell lines offer the potential of growing sufficient numbers of
cells in an extracorporeal mass cell culture system, or bioreactor,
for sustaining a patient because the growth of cell lines is not
limited by cell senescence, but by nutrient availability. Primary
human or animal liver cells can also be obtained in the numbers
required for a functional bioartificial liver. However, the use of
human liver for cell preparation is limited by its lack of
availability, and the use of animal liver for cell preparation
suffers from some degree of cellular incompatibility. Acute
cellular incompatibility results from the binding of antibodies
that recognize foreign cells followed by the binding of proteins of
the complement system and lysis of the foreign cells. Longer-term
cellular incompatibility mechanisms also exist, but should not
present any problems for the use of bioreactors as interim or
"bridge" medical products. A possible alternative to initial
inoculation with a large mass of differentiated cells is the
expansion of liver stem cells that are progenitors of mature liver
cells. Recent reports suggest that liver progenitor cells go
through multiple cell divisions on the path toward maturation and
differentiation (Brill, S. et al., Differentiation 1995, 59, 95;
Sigal S. H. et al., Differentiation 1995, 59, 35). Suitable control
of the growth and differentiation processes with staged application
of appropriate cytokines can permit preparation of a clinically
useful quantity of cells.
[0012] 2) Providing for a critical minimum mass of cells. The adult
human liver has a mass of about 1400-1600 grams, and features a
considerable reserve, or redundant, capacity. It is estimated that
human survival can be sustained with about 15-20% of the total
liver mass. The figure of 20% of the liver mass corresponds to
about 5.times.10.sup.10 cells (Kasai et al. Artif Organs 1994, 18,
348). Most, if not all, previous bioartificial liver designs suffer
from a woefully inadequate cell capacity. That is, such devices are
capable of sustaining far fewer than 5.times.10.sup.10 cells, often
orders of magnitude fewer cells. Without the cell mass critical for
biosynthesis of plasma components and detoxification reactions,
these other designs have little clinical utility.
[0013] 3) Supplying oxygen to the cells. The functional units of
most organs such as nephron, acinus, alveoli, microvilli, skin,
etc. consists of a capillary bed across which is a physico-chemical
gradient. These gradients are controlled by mass transfer effects.
Oxygen is the primary nutrient that is limiting in cell cultures
(Macdonald, J. M. et al. NMR Biomed 1998, 11, 1; Glacken M. W. et
al. Ann NY Acad Sci 1983, 413, 355). `Integral` oxygenation, or
aeration inside the bioreactor containing the biological or
chemical material of interest, greatly enhances mass transfer of
oxygen and carbonic acid. The formation of the latter can be used
to control pH.
[0014] Oxygen is generally the limiting nutrient in hollow fiber
bioartificial livers (Catapano, G. et al. Int J Art Organs 1996,
19, 61) primarily because hepatocytes are highly aerobic cells
which causes problems of oxygen mass transfer. Oxygen has a
relatively high diffusion coefficient and its mass transfer from
blood in the liver sinusoids to hepatocytes is dominated by
diffusion rather than convection (i.e., convection and perfusion
are caused by pressure gradients). These effects are because an
oxygen molecule is much smaller than other nutrients such as a
glucose molecule, or than biosynthetic products such as proteins,
and because the hepatocytes generate steep concentration gradients
in bioartifical livers. With known rates of oxygen diffusion and
oxygen consumption, and reasonable estimates of cell density, the
diffusion distance at which oxygen utilization becomes the
rate-limiting factor for growth is approximately 200 .mu.m
(Macdonald, J. M. et al., 1999, in Cell Encapsulation Technology
and Therapeutics, Kuhtreiber, W., Lanza, R. P. and Chick, W. L.
(Eds.) Birkhauser Boston, Cambridge, pp. 252-286. In bioartificial
livers with serial oxygenation aerated with air, oxygen becomes
axially limiting in perfusion media by 25 mm (Macdonald et al.,
1999, supra).
[0015] Hepatocytes have a high metabolic rate and require a
continuous oxygen supply. The oxygen consumption rate ranges from
0.59 to 0.7 nmole/s/10.sup.6 cells for HepG2 cells (Smith, M. D. et
al Int J Artif Organs 1996, 19, 36) and is 0.42 nmole/s/10.sup.6
cells for isolated hepatocytes (Rotem, A. et al. Biotech Bioeng
1992, 40, 1286). Integral oxygenation, that is, continuous supply
of oxygen along the path of media supply to the cells, is essential
to supplying oxygen to liver cells. Serial oxygenation, which is
oxygenation at one or a few places in the fluid line of media
supply cannot sustain the mass of liver cells needed for an
effective bioartificial liver. A difficulty with serial oxygenation
is that the solubility of oxygen in aqueous media unsupplemented
with oxygen carriers is so low that any oxygen present is quickly
depleted by cell metabolism. In fact, in longitudinal flow along a
conventional bioreactor semipermeable membrane, hepatocytes deplete
oxygen within 2.5 centimeters along the path and therefore
convective oxygen mass transfer via increasing Starling flow is
improved. Increasing flow rates through conventional bioreactors
can cause fiber breeches and adversely affect hepatocyte function
(Callies, R. et al., Bio/Technology 1994 12:75). Thus,
bioartificial liver designs that do not provide for adequate oxygen
delivery are able to support only a limited number of cells. In
addition, the flux of oxygen in a diffusion-limited system
constrains cells to grow very near (less than about 0.2 mm) to the
supply of oxygen. For example, U.S. Pat. No. 5,622,857 to Goffe
discloses a bioreactor with some coaxial and some parallel
semi-permeable hollow fibers. The Goffe design allows integral
oxygenation but does not constrain the thickness of the cell
compartment. The fiber-to-fiber spacing in that design is 3-5 mm so
that there is not strict control of the oxygen diffusion distance.
Similarly, U.S. Pat. No. 5,183,566 to Darnell et al. discloses a
bioreactor with bundles of hollow fibers in parallel. The Darnell
et al. design does not permit a multitude of individual
multi-coaxial fiber bundles to be built-up with accurate and
reproducible diffusion distances, and the design is not easily
scaled-up. The Darnell et al. design uses bundles of parallel
fibers, again not effectively addressing the issue of oxygen
diffusion. Thus, a need remains for a bioreactor which deals
effectively with the diffusion-limited thickness of the cell mass,
with providing a critical mass of cells, and with supplying oxygen
throughout the length of the bioreactor without adverse shear force
effects.
[0016] 4) Supplying nutrients to the cells, and removing cell waste
products efficiently. The issue of supplying nutrients such as
carbohydrates, lipids, minerals, and vitamins has been successfully
solved by several variants of hollow fiber technology, and these
features must be successfully incorporated into any viable
bioartificial liver or bioartificial organ design. Similarly, the
issue of removing metabolic wastes is usually handled by the same
system that supplies the nutrients. The consumption rates for
glutamate, pyruvate, and glucose are typically in the range of 0.03
to 0.3 nmol/s/10.sup.6 cells, with reasonable assumptions for cell
density and growth rate (Cremmer, T. et al. J Cell Physiol 1981,
106, 99; Imamura, T. et al. Anal Biochem 1982, 124, 353; Glacken,
M. Dissertation 1987). The diffusion rates of oxygen in tissue are
similar to those of pyruvate in water, and higher than those of
glucose. As these consumption rates are less than the oxygen
consumption rate, oxygen is the limiting nutrient in most
conditions.
[0017] 5) Limiting shearforces and hydrostatic pressure. For a
given bioreactor there is an optimum balance of convection and
diffusion for adequate oxygen mass transfer without creation of
severe oxygen gradients. For example, using a nontoxic oxygen
range, <0.4 mM (solubility constant is 1.06 mM/atm, for air
solubility is 0.2 mM at 37.degree. C.), the convective component of
oxygen mass transfer should be increased as cells are increasingly
farther than 0.2 mm from supply of oxygen (Macdonald et al., 1999,
supra.). Although the partial oxygen tension in the liver sinusoid
is about 70 mm Hg near the portal triad dropping to 20 mm Hg near
the central vein, which equates to a range of 0.096 to 0.027 mM of
free oxygen, the hemoglobin-bound oxygen ranges from 6.26 to 2.91
mM. The velocity of blood flow in the liver sinusoid is about 0.02
cm/s while the oxygen diffusion coefficient is about 4
orders-of-magnitude less, or 2.times.10.sup.-6 cm.sup.2/s. However,
hepatic function is adversely affected with increasing shear
forces, and in vivo hepatocytes are protected by a layer of
endothelia and extracellular matrix in the space of Disse.
Sufficient shear forces will kill hepatocytes. Others have found
that shear forces induce specific cytochrome P450's (Mufti N. A.
and Shuler, M. L., Biotechnol. Prog., 1995, 11, 659). A recent
study has shown that liver regenerates faster with 90% than with
70% hepatectomy and this was attributed to greater shear forces
(Sato, Y. et al., Surg. Today, 1997, 27, 518). However, this faster
regeneration could also be due to enhanced oxygen, nutrient, and
agonist mass transfer. Therefore, there is some maximum level of
shear force that hepatocytes can sustain while still displaying
optimal function. This maximum level can be increased if a layer of
endothelia protects hepatocytes.
[0018] To increase convection, hydrostatic pressure gradients are
increased. Elevated hydrostatic pressures can implode hepatocytes.
Therefore, it is important to stay below these pressures. It is
possible to cause 100% mortality of isolated rat hepatocytes by
generating hydrostatic pressures of greater than 7 psi (>300 mm
Hg) for longer than 2 minutes while inoculating these cells into
coaxial bioreactor using a syringe.
[0019] 6) Inducing or sustaining a differentiated cell phenotype
with the capacity for biosynthesis and biotransformation of toxins.
The use of the differentiated phenotype of liver cells is necessary
to produce a useful bioartificial liver because the specialized
functions of the liver, including biosynthesis of blood components
and detoxification of toxins, are associated with the
differentiated phenotype. These specialized functions are lost in
whole, or in part, as the cells dedifferentiate, which often
happens in isolated primary cell culture. In contrast, the form of
liver cells capable of rapid growth is the dedifferentiated
phenotype, leaving the practitioner to balance two opposing needs
(Enat, R. et al. Proc Natl Acad Sci USA, 1984, 81, 1411). Some
reports suggest that the phenotype of liver cells may be modulated
by the presence of cytokines and extracellular matrix components.
In particular, the extracellular matrix components rich in collagen
IV and laminin, produced by the Engelbrech-Holm Sarcoma (EHS) cells
and available commercially as MATRIGEL.TM., when used with
hormonally defined media induces a differentiated phenotype (Enat,
R. et al., supra; Bissell, D. M. Scan J Gasterenterol-Suppl 1988,
151,1; Brill, S. et al. Proc Soc Exp Biol Med 1993, 204, 261).
[0020] 7) Maintaining sterility. The implementation of facile
sterilization procedures for bioreactors and associated components
is essential for clinical utility of extracorporeal bioartificial
organs. Fortunately, the procedures for sterilization are well
established, including standard methods both for sterilization of
extracorporeal devices and for maintaining asepsis by standard
in-line filters.
[0021] 8) Preventing liver tissue rejection or lysis by complement.
Rejection of foreign tissue may occur by a rapid process known as
complement-mediated lysis that involves binding of circulating
antibodies to the foreign cell surface, attachment of the proteins
of the complement system, and lysis of the offending cell. The
cell-mediated immune system is responsible for delayed rejection
reactions. However, the cell-mediated immune system should not play
a major role in bioreactor systems that do not permit direct
contact of host and donor cells. Foreign body reactions, for
example, against the structural components of bioreactors, are also
cell-mediated and should therefore not constitute substantial
obstacles.
Needed Improvements.
[0022] In view of the above, a clear need exists for bioartificial
livers to sustain patients in liver failure. Specifically, a need
exists for an improved version of a bioartificial liver that would
have a high biological cell capacity in very thin layers of cells,
readily accessible to oxygen and nutrients. There is a need for an
apparatus or bioreactor, that provides efficient oxygen delivery to
large masses of cells in cell culture and permits transfer of
beneficial biosynthetic cell products to the patient. Similarly,
there exists a need for effective methods of use of such an
apparatus.
[0023] The problems with existing bioreactor designs include
inadequate oxygenation, minimal capacity for the biological cell
component, limited capability for removal of toxins, excessive
shear and hydrostatic forces, and difficulty in transferring
biosynthetic cell products for patient use. In addition, existing
bioreactor designs have not dealt effectively with the
diffusion-limited thickness of the cell mass, with providing a
critical mass of cells, and with supplying oxygen throughout the
length of the bioreactor.
3. SUMMARY OF THE INVENTION
[0024] It is therefore an object of the present invention to
provide varying embodiments of an apparatus which provides
efficient oxygen delivery to large masses of cells in a bioreactor
cell culture and transfer of beneficial biosynthetic cell products
to the patient, and methods of use therefor.
[0025] It is a further object of the present invention to provide
an apparatus which permits cells to be contained in a thin annular
space adjacent to continuously oxygenated and flowing nutrient
medium that provides essential oxygen and nutrients and carries
away metabolic products.
[0026] It is a still further object of the present invention to
provide an apparatus for the collection of the biosynthetic
products of large masses of cells in a bioreactor.
[0027] It is a still further object of the present invention to
provide an apparatus to detoxify blood or plasma from a patient
unable to remove or inactivate these toxins.
[0028] It is a still further object of the present invention to
provide an apparatus to serve as a substitute liver.
[0029] The present invention provides a scaled-up multi-coaxial
hollow fiber bioreactor, having: a housing having an inner side;
and an array of about 20 to about 400 modules of hollow fibers,
each module having at least three coaxial semipermeable hollow
fibers. The module of hollow fibers has a first fiber nested within
a second fiber; the second fiber nested within a third fiber; and
so on. Each fiber has an inner side and an outer side. A first
compartment is defined by the inner side of the first fiber, and
has at least one first inlet port and at least one first outlet
port. A second compartment is defined by a first annular space
between the outer side of the first fiber and the inner side of the
second fiber, and has at least one second inlet port and at least
one second outlet port. A third compartment is defined by a second
annular space between the outer side of the second fiber and the
inner side of the third fiber, and has at least one third inlet
port and at least one third outlet port; and successive
compartments are defined by the adjacent fibers. An outermost
compartment for permitting integral aeration is defined by an
annular space between the outer side of the outermost fiber and the
inner side of the housing, and has at least one outermost inlet
port, and at least one outermost outlet port. The housing has at
least one inlet manifold and at least one outlet manifold for each
compartment.
[0030] An additional embodiment of the present invention features a
serially-linked bioreactor with multiple scaled-up multi-coaxial
hollow fiber bioreactors in which two or more compartments are
connected in a continuous and serial manner. This implementation is
particularly useful for both the biotransformation of toxins in
patient plasma and the biosynthesis of plasma components to
supplement patient blood.
[0031] A further embodiment of the present invention includes a
one-sided multi-coaxial hollow fiber bioreactor that is
particularly adapted to NMR studies and uses in which access to all
ports from one side or one end is necessary.
[0032] Yet a further embodiment of the present invention includes a
two-sided multi-coaxial hollow fiber bioreactor that is
particularly adapted to small scale investigations.
[0033] A still further embodiment of the present invention includes
a tight-packed hollow fiber bioreactor. This implementation is
particularly useful for high density culture of cells in a compact
arrangement and is suitable for both the transformation of toxins
in patient plasma and the biosynthesis of plasma components to
supplement patient blood.
[0034] The bioreactor of the present invention, when used as a
bioartificial liver, has a modular design to allow an easy
adjustment in liver functional capacity depending on the weight of
the patient, whether that patient is infant, child, adolescent or
adult, man or woman, and on the degree of remaining liver function
in the patient. The bioreactor of the present invention further has
both plasma and nutrient medium compartments to permit the
biotransformation of toxins in the patient plasma and to enhance
the effective transfer of biosynthetic products from the
bioartificial liver to the patient. When used with liver or other
cells, this invention is useful in the preparation of biosynthetic
products for patients, in experimental use, and use as a
supplemental biotransformation apparatus for detoxification of
blood. The toxins in the blood may include, but are in no way
limited to, metabolic wastes, products of cell or erythrocyte
break-down, overdoses of ethical pharmacologic agents such as
acetaminophen, and overdoses of illicit pharmacologic agents. Ease
of manufacture of the invention enables cost-effective commercial
development.
[0035] There has thus been outlined, rather broadly, the more
important features of the invention in order that the detailed
description thereof that follows may be better understood, and in
order that the present contribution to the art may be better
appreciated. There are, of course, additional features of the
invention that will be described hereinafter and which will form
the subject matter of the claims appended hereto.
[0036] In this respect, before explaining at least one embodiment
of the invention in detail, it is to be understood that the
invention is not limited in its application to the details of
construction and to the arrangements of the components set forth in
the following description or illustrated in the drawings. The
invention is capable of other embodiments and of being practiced
and carried out in various ways. Also, it is to be understood that
the phraseology and terminology employed herein are for the purpose
of description and should not be regarded as limiting.
[0037] As such, those skilled in the art will appreciate that the
conception, upon which this disclosure is based, may readily be
utilized as a basis for the designing of other structures, methods
and systems for carrying out the several purposes of the present
invention. It is important, therefore, that the claims be regarded
as including such equivalent constructions insofar as they do not
depart from the spirit and scope of the present invention.
[0038] Further, the purpose of the foregoing abstract is to enable
the U.S. Patent and Trademark Office and the public generally, and
especially the scientists, engineers and practitioners in the art
who are not familiar with patent or legal terms or phraseology, to
determine quickly from a cursory inspection the nature and essence
of the technical disclosure of the application. The abstract is
neither intended to define the invention of the application, which
is measured by the claims, nor is it intended to be limiting as to
the scope of the invention in any way.
[0039] These together with other objects of the invention, along
with the various features of novelty which characterize the
invention, are pointed out with particularity in the claims annexed
to and forming a part of this disclosure. For a better
understanding of the invention, its operating advantages and the
specific objects attained by its uses, reference should be had to
the accompanying drawings and descriptive matter in which there is
illustrated preferred embodiments of the invention.
4. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] FIG. 1A illustrates a partial view of a multi-coaxial fiber
unit comprising a plurality of compartments.
[0041] FIG. 1B illustrates a graphical representation of radial
oxygen concentrations.
[0042] FIG. 1C illustrates a graphical representation of axial
oxygen concentrations.
[0043] FIG. 2A illustrates an elevation view of a multi-coaxial
fiber bioreactor.
[0044] FIG. 2B illustrates an enlarged view of a detail of a
multi-coaxial fiber unit.
[0045] FIG. 3A illustrates a set of components for centering the
fibers.
[0046] FIG. 3B illustrates a detail of the spacer.
[0047] FIG. 3C illustrates the fiber clips.
[0048] FIG. 3D illustrates a detail of the arrangement of manifolds
for the bioreactor.
[0049] FIG. 3E provides an alternative illustration of the
manifolds.
[0050] FIG. 4 illustrates the four main steps for two procedures
used to construct multicoaxial bioreactors.
[0051] FIG. 5 illustrates a general process of thermoplastic
welding hollow fibers.
[0052] FIG. 6A illustrates a perspective view of a two sided
embodiment of a bioreactor.
[0053] FIG. 6B illustrates a detail of the front side of the first
manifold.
[0054] FIG. 6C illustrates a detail of the back side of the first
manifold.
[0055] FIG. 6D illustrates an exploded view of the first manifold
and associated elements.
[0056] FIG. 6E illustrates detail of the front side of the second
manifold.
[0057] FIG. 6F illustrates a detail of the front side of the second
manifold.
[0058] FIG. 6G illustrates a detail of the back side of the second
manifold.
[0059] FIG. 6H illustrates a collar and a detail of the
manifold.
[0060] FIG. 6I is a cross-section of the second manifold.
[0061] FIG. 6J illustrates a detail of the front-side of the third
manifold.
[0062] FIG. 6K illustrates a front perspective of the third
manifold.
[0063] FIG. 6L illustrates a back view of the third manifold.
[0064] FIG. 6M illustrates a cross-section of the second and third
manifolds.
[0065] FIG. 6N provides a plan view of the complete assembly of a
two sided bioreactor.
[0066] FIG. 7 illustrates a stand for mass producing
bioreactors.
[0067] FIG. 8 illustrates a perspective view of a one sided
bioreactor.
[0068] FIG. 9 illustrates a small one-sided bioreactor with
integral oxygenation.
[0069] FIG. 10A further illustrates a serially linked bioreactor
with an elevation view.
[0070] FIG. 10B illustrates radial flow of the serially-linked
bioartificial liver with a detail view.
[0071] FIG. 10C illustrates radial flow of the serially-linked
bioartificial liver with a detail view.
[0072] FIG. 11A illustrates the variables used in the
implementation of Darcy's law.
[0073] FIG. 11B illustrates a relationship between radial flow rate
and a pressure differential.
[0074] FIG. 11C illustrates a relationship between a radial flow
rate and pressure in one cell compartment.
[0075] FIG. 12 illustrates the algorithm for the selection of
hollow fiber characteristics for attaining superior physiological
function and cell viability.
[0076] FIG. 13A illustrates a cross section of a multi-coaxial
bioreactor.
[0077] FIG. 13B illustrates a cross section of an alternative
embodiment of a multi-coaxial bioreactor.
[0078] FIG. 14 illustrates perspective view of an embodiment of a
bioreactor.
[0079] FIG. 15 illustrates a perspective view of a device used in
the construction of a bioreactor.
5. DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0080] 5.1 Definitions
[0081] Annular space. The radial distance separating two adjacent
hollow fibers.
[0082] BAL. Bioartificial liver. Also, specific embodiments of the
present invention: the scaled-up multi-coaxial hollow fiber
bioreactor, the tight packed hollow fiber bioreactor or the
serially-linked bioreactor with a complement of liver cells,
nutrient medium, and gases.
[0083] Bioreactor module. Coaxially-arranged semipermeable hollow
fibers. One module forms the core of the multi-coaxial hollow fiber
bioreactor whereas the scaled-up multi-coaxial hollow fiber
bioreactor comprises many modules.
[0084] Biotransformation. The metabolic detoxification of blood or
plasma by tissues or cells.
[0085] Fourth compartment. The compartment, if present, in a
bioreactor embodiment that is bounded by the outside of the third
hollow fiber and the inside of the fourth, that is, adjacent,
hollow fiber, and is connected to two ports, the fourth compartment
inlet port and the fourth compartment outlet port.
[0086] First compartment. The compartment in any of the bioreactor
embodiments that is bounded in part by the inside of the first and
innermost coaxial hollow fiber and is connected to two ports, the
first compartment inlet port and the first compartment outlet
port.
[0087] Integral aeration. Exposure to a gas, typically air or
oxygen with carbon dioxide, at almost all points along a flow path.
Integral aeration is distinguished from serial aeration, in which a
bubbler or gas exchange device is inserted at one point in the
fluid circuit.
[0088] Manifold. A part of the bioreactor located at an end of the
fibers and intended to physically separate compartments and split
flow of fluids.
[0089] Microfiber or microbore hollow fiber. A semipermeable hollow
fiber of 200 to 500 micrometer o.d.
[0090] Multi-coaxial hollow fiber bioreactor. The bioreactor
comprising three or more coaxially-arranged semi-permeable hollow
fibers encased by a hollow housing.
[0091] Nutrient medium. The balanced electrolyte solutions enriched
with sugars, trace minerals, vitamins, and growth enhancers. Each
particular formulation is named by or for the formulator, sometimes
with whimsical or non-illuminating designations. Nutrient media
include, but are not limited to: RPMI 1640 (Roswell Park Memorial
Institute, formulation #1640), Ham's F-12 (the twelfth formulation
by Dr. Ham in his F series), DMEM (Dulbecco's modified Eagle's
medium), and CMRL-1415 (Connaught Medical Research Laboratory
formulation #1415). Nutrient media are routinely enhanced by
addition of hormones, minerals, and factors known to those of
ordinary skill in the art, including, but in no way limited to,
insulin, selenium, transferrin, serum, and plasma.
[0092] One-sided multi-coaxial hollow fiber bioreactor. The version
of the multi-coaxial hollow fiber bioreactor that has both inlet
and outlet ports on the same end plate. This version is
particularly adapted to NMR studies and to studies where access to
all ports from one side is necessary.
[0093] Outermost compartment. The compartment in any of the
bioreactors that is bounded by the outside of the outermost hollow
fibers and the inside of the housing, and is connected to two
ports, the outermost compartment inlet port and the outermost
compartment outlet port.
[0094] Potting. A term of the art meaning the joining of elements,
as by gluing, or any other suitable means.
[0095] Scaled-up multi-coaxial hollow fiber bioreactor. The
bioreactor comprising arrays of from about 20 modules to about 400
modules of coaxially-arranged semi-permeable hollow fibers, where
the entire set of modules is encased by a hollow housing.
[0096] Second compartment. The compartment in a bioreactor
embodiment that is bounded by the outside of the first and
innermost coaxial hollow fiber and the inside of the second, that
is, adjacent, coaxial hollow fiber, and is connected to two ports,
the second compartment inlet port and the second compartment outlet
port. In the one-sided multi-coaxial hollow fiber bioreactor and in
some dead-ended fiber designs only one port provides access to
compartment 2.
[0097] Serially-linked bioreactor. The system comprising a
plurality of scaled-up multi-coaxial hollow fiber bioreactors or of
tight-packed hollow fiber bioreactors, or a combination, in which
two or more compartments are connected in a continuous and serial
manner. In this context, each scaled-up bioreactor is referred to
as a bioreactor subunit.
[0098] Third compartment. The compartment in any of the bioreactor
embodiments that is bounded by the outside of the second hollow
fiber and the inside of the third, that is, adjacent, coaxial
hollow fiber, and is connected to two ports, the third compartment
inlet port and the third compartment outlet port.
[0099] Tight-packed hollow fiber bioreactor. The scaled-up
bioreactor comprising arrays of from about 20 modules to about 400
modules of coaxially-arranged semi-permeable hollow fibers.
Microfibers for aeration are arranged parallel and adjacent to the
modules and the whole encased by a hollow housing.
[0100] 5.2 Elements of the Apparatus
[0101] The instant invention includes a modular multi-coaxial
bioreactor, having in theory, no limit to the number of coaxial
fibers. In a preferred embodiment a scaled-up multi-coaxial
bioreactor comprises at least two sets of manifolds, at least three
hollow fiber sizes, at least two sets of endcaps, and a housing.
This embodiment of the bioreactor contains at least four separated
compartments. The modular design is composed of two sets of
manifolds, with each pair of manifolds connected to each end of the
fibers. There is a series of about 20 to about 400 holes coaxially
arranged across the sets of manifolds and coaxially aligning the
fibers. The manifolds optionally include flow distributors so that
fluid and gas phase flow rates through the fibers are approximately
uniform. The fiber manifold assemblies are attached radially from
the largest to the smallest diameter fibers, and axially from the
smallest to the largest diameter fibers. Fibers with smaller
diameter are inserted into fibers of larger diameter and the
respective manifolds are sealed together. To align fibers, two or
more dowels are inserted through precisely drilled holes in the
three manifolds or by interconnecting tongue and grooves on
adjacent manifolds.
[0102] The bioreactors of the current invention advantageously
combine `integral` oxygenation with defined diffusion distances,
have ports to accommodate potential bile duct formation, and/or are
easily scalable. Integral oxygenation permits efficient mass
transfer of dissolved gases and control of pH. Defined diffusion
distances permit predictable axial and radial
physico-chemico-biological parameters such as shear forces,
availability of nutrients, and pH. In use with patients, one or
more of the at least four compartments can be used for patient
blood plasma while another can be used to perfuse cells with
integrally oxygenated media. Optionally, two or more bioreactor
units are attachable in series so that toxins can perfuse out of
plasma radially through the cell mass in one unit and infuse
synthetic factors in the next unit. There is the potential for the
biliary system to develop using the ports as the bile duct exit
ports.
[0103] FIG. 1A illustrates a multi-coaxial fiber unit according to
the instant invention comprising a plurality of compartments.
Innermost fiber 102 provides intracapillary space or first
compartment 104 for the receipt of standard media or plasma. Middle
fiber 106 provides annular space or first middle compartment 108
for the containment of cells such as liver cells. Outer fiber 110
provides extracapillary space or second middle compartment 112 for
the receipt of media. Housing 114 defines the outermost perimeter
of the multi-coaxial fiber unit. Space or outermost compartment 116
between housing 114 and outer fiber 110 allows for the receipt of a
gas. Diffusion distance 118 is half the width of first middle
compartment 108. Radial perfusion 120 is the radial flow of, for
example, dissolved oxygen through the fiber unit, while axial
perfusion 122 is the axial flow of, for example, dissolved oxygen
through the fiber unit.
[0104] FIG. 1B shows a radial oxygen gradient across the first
middle compartment 108 of a coaxial bioreactor having viable cells
and integral oxygenation, where oxygen concentration is equal in
the first compartment 104 and second middle compartment 112, and an
annular space 126 of 0.4 mm (millimeters) separators 102 and 106.
As shown, oxygen percentage 124 approaches zero as distance 126
approaches the diffusion distance 118 of 0.2 mm. As distance
approaches 0.4 mm, percentage oxygen 124 approaches 100 percent,
again due to oxygen diffusion from the second middle compartment
112.
[0105] FIG. 1C shows axial oxygen gradients obtained through the
use of bioartificial liver bioreactor designs having either
"in-series" or "in-parallel" oxygenation. As shown, percentage of
oxygen 128 decreases with distance 130 when "in series" 132
oxygenation is used, but remains nearly constant when "in parallel"
134 oxygenation is used, thereby demonstrating the decreased axial
oxygen gradient due to integral oxygenation.
[0106] This invention permits precise control of desired diffusion
distances in conjunction with integral oxygenation, and the modular
design in conjunction with the potting material permits fibers of
any composition to be arranged in a desired multi-coaxial order.
Potting materials are known to those skilled in the art; such as
that disclosed in U.S. Pat. No. 4,227,295 to Bodnar et al., which
is herein incorporated by reference in its entirety. Where
thermoplastic fibers are used, such as polypropylene, polyethylene,
polysulfone, etc., then bioreactors can be constructed using a
thermal bonding method such as described by Robinson in U.S. Pat.
No. 5,015,585.
[0107] FIG. 2A illustrates a scaled-up multi-coaxial bioreactor
comprising a plurality of multi-coaxial fiber units. In a preferred
embodiment, the bioreactor comprises from about 20 to about 400
multi-coaxial fiber modules contained in housing 202. However, in
theory, there is no limit to the number of coaxial fibers. As
shown, housing 202 is 17 centimeters in length 204 with an 8
centimeter diameter 206, although alternative dimensions are
envisioned. For example, the length of fibers can be from about 2
centimeters to about 50 centimeters and the diameter can be from
about 1 centimeter to about 100 centimeters. Housing 202, for
example, comprises three sets of manifolds 208, and one set of
endcaps 210, one for each respective end of the bioreactor. One set
of manifolds is needed for each size of hollow fiber. The housing
is constructed of glass, polycarbonate, polypropylene,
polyethylene, Delrin, Teflon, steel, brass, ceramic, or any other
suitable material. Manifolds 208 and endcaps 210 can be machined or
formed from acrylic, thermoplastic, ceramic, or any other suitable
material. The hollow fibers comprising each multi-coaxial fiber
module are preferably semi-permeable, and are in each of, for
example, 3 sizes: approximately 5 millimeter outer diameter (o.d.)
polysulfone; approximately 3 millimeter o.d. polysulfone; and
approximately 1 millimeter o.d. cellulose acetate. There are thus
three fibers per coaxial fiber unit, and three manifolds per module
of fibers with the manifolds connected to each end of the fibers.
The desired .DELTA.P can also be created by restricting the
effluent flow rate from port 212, for example by use of a needle
valve. The invention also envisions embodiments having more than
three coaxial fibers in each fiber module, with corresponding
manifolds and ports.
[0108] Each bioreactor of the above listed or similar dimensions
can support up to about 160 grams of tissue. Furthermore, in
another embodiment a larger cell mass capacity is supported by
using a larger annular compartment for the cell compartment and/or
using longer fibers. An annular design for the cell compartment has
an additional advantage over using single tubes because orders of
magnitude greater biomass can be obtained. For example, a
bioartificial liver described by Hu et al., U.S. Pat. No. 5,605,835
where hepatocytes are encapsulated in collagen in the innermost
intracapillary compartment, would require 44,860 cellulose acetate
hollow fibers of 200 micrometer diameter to attain the about 120
grams of tissue needed as an extracorporeal liver. In contrast, the
embodiment of the present invention illustrated by FIG. 2 uses a
factor of 150-fold fewer fibers.
[0109] Openings leading to ports allow for the movement of
materials. Innermost ports 212 allow for the flow of media or
plasma through the bioreactor. First middle ports 214 allow for the
inoculation of cells into, or flow of cells through, the
bioreactor. Second middle ports 216 allow for the flow of media
through the bioreactor. Lastly, outermost ports 218 allow for the
flow of gas through the bioreactor. Alternative uses of ports are
also envisioned. For example, media can flow through ports 218,
cells into, or through, ports 216, media or plasma through 214, and
oxygen or other gases through 212.
[0110] FIG. 2B illustrates an enlarged view of a multi-coaxial
fiber unit comprising a plurality of compartments located within
the multi-coaxial bioreactor. As shown, media or plasma residing
within first compartment 104 can either flow to or be received from
innermost port 212. Similarly: (1) cells residing within first
middle compartment 108 can either flow to, or be received from
first middle port 214; (2) media located within second middle
compartment 112 can either flow to, or be received from second
middle port 216; and (3) gas residing within outermost compartment
116 can either flow to, or be received from outermost port 218.
Also depicted is a module of hollow fibers consisting of innermost
fiber 220, middle fiber 222 and outermost fiber 224. Embodiments
comprising modules with more than one middle fiber are also
envisioned.
[0111] FIG. 3A further illustrates a set of manifolds 208,
including first manifold 302, second manifold 304, and third
manifold 306. The manifolds each consist of a circular region about
15 centimeters in diameter, each with about 20 to about 400 holes,
although any number of holes is possible. The holes are of three
different diameters corresponding to the outer diameter of the
respective fibers. This permits 20 fibers per row with a 2 mm space
between holes, although optimum hole patterns are based on the
number of desired fiber modules. These fibers can consist of any
desired hollow fiber or tube with appropriate changes in the design
specifications of the respective parts to fit the respective fiber
diameters.
[0112] Two exemplary potting procedures are described: one that
results in centered coaxial fibers, and one that does not. In both
procedures the fibers are inserted into respective manifolds 208.
The outer fiber 110 can be composed of any air permeable material
such as, silicon, ceramic, glass, etc. As an example, polypropylene
outer hollow fibers can be used in conjunction with thermoplastic
welding.
[0113] The potting procedure used to center the fiber requires
three additional sets of parts shown in FIGS. 3A, 3B and 3C: (1)
first hollow fiber guide 314 for first manifold, second hollow
fiber guide 316 for second manifold, and third hollow fiber guide
318 for third manifold, (2) spacers 320, and (3) hollow fibers
clips (outer 322, middle, 324, and inner, 326) for each respective
hollow fiber size (outer 110, middle 106, and inner 102). The
hollow fiber guides can be composed of any material that can
maintain rigidity at 3 mm thickness. The manifold and hollow fiber
guide are placed against each other, sequential manifold holes are
aligned with dowels, and outer fibers 110 are inserted through the
holes of the manifold and then the hollow fiber guide with the ends
of the fibers extending at least 1 cm beyond hollow fiber guide.
The fibers are inserted in the housing 202 and the other end of the
outer fibers are inserted into next first manifold 302 and first
hollow fiber guide. The hollow fiber guide is extended away from
manifold a distance permitting the pair of spacers 320 to slide
between manifold and hollow fiber guide. The spacers 320 are glued
on respective sides to adjacent manifold extensions 330. Once
manifolds 208, spacer 320, and hollow fiber guide are secured, the
hollow fibers are secured with tape or clips. Outer 322, middle
324, and inner 326 fiber clips that fit each fiber size are
inserted across each row of fibers serving to keep fibers taut to
maintain coaxiality and to pinch close the inner lumen so epoxy
will not clog hollow fiber during potting. Therefore, fiber clips
are varying lengths depending on row length. The secured fibers,
spacer, and hollow fiber guide are inserted into a casting pot 312
which is screwed on or sealed to manifold 208 and serves to retains
the epoxy during the potting process. The assembly is placed
upright with casting pot 312 on the bottom and with a 10 to 45
degree downward tilt toward port 305 potting material, e.g., epoxy,
is injected into side port 305 and runs down the side of the
manifold 208 through holes 332 filling voids 334 contained by
casting port 312. The bottom of the casting pot 312 is tapped to
remove air bubbles. An appropriate amount of epoxy is added to fill
voids 334 and to a level to cover both sides of manifold 308. Once
the epoxy has nearly cured, the hollow fiber guide, spacer 320,
casting pot 312, and epoxy is cut off leaving a very small layer of
epoxy 308 over manifold. Therefore, the spacers 320, hollow fiber
guides 314, 316, 318 and fiber clips 322, 324 and 326 serve two
purposes: (1) they keep fibers taut and centered while potted, and
(2) create a region for epoxy to cure between hollow fiber
interstices that can be cut leaving a layer of epoxy 308 over
manifolds 208.
[0114] Other methods can be used to center the inner fiber. In a
first example, a rigid rod is inserted into the lumen of the inner
fiber to center it. Then cells are mixed with a
temperature-dependent gelling matrix, such as collagen, and the
matrix is induced to gel. Then, the rod is removed. In a second
example, a monofilament fiber with a diameter equal to the
necessary inter-fiber spacing acts as a spacer. The monofilament
made of polypropylene, polyethylene, or other appropriate material
is helically wound around the inner fiber with one complete
revolution every centimeter or so. The inner fiber with its
monofilament winding is then inserted into the middle fiber. This
permits the inner and middle fibers to be axisymetric. Therefore,
the inoculated cells undergo a cork screw-type path. The
monofilament is potted with the inner fiber using element 306.
[0115] FIG. 3D illustrates a cut out and enlarged view of a
multi-coaxial fiber unit comprising a plurality of compartments
located within the multi-coaxial bioreactor and formed by the
centered coaxial fiber process. Thus, first manifold 302 is bound
on the top and bottom by epoxy 308 and partially defines outermost
compartment 116 and second middle port 216. Second manifold 304 is
bound on the top and bottom by epoxy 308 and partially defines
second middle port 216 and first middle port 214. Third manifold
306 is bound on the top and bottom by epoxy 308 and partially
defines innermost port 212.
[0116] The potting process resulting in non-centered fibers does
not require hollow fiber guides, monofilament, or spacers but
requires a centrifuge. FIG. 3E is an illustration of three sets of
manifolds 208, showing first manifold 302, second manifold 304,
third manifold 306, and casting pot 312. Note the second manifold
304 and third manifold 306 do not have holes and will not coaxially
align fibers. The epoxy potting process is described by Bodnar et
al. (U.S. Pat. No. 4,227,295) herein incorporated by reference in
its entirety. This process involves inserting the fiber ends into
the two respective manifolds. The fibers ends are gathered and then
secured and sealed with tape, string, or some other material. Then,
the casting pots 312 are attached to both ends. The assembly is
attached to a centrifuge rotor at the axial center of the assembly.
A small flat container is placed above the assembly, and has holes
at each end which are attached to the ports 305 at each end of the
assembly. As the centrifuge rotates, epoxy is placed in the middle
of the container and is forced out toward the ends of the
container, down the holes of the container, through the ports 305,
and into the casting pots 312 filling the interstices of the fiber
bundle. Once the appropriate amount of epoxy has flowed to the
casting pots 312, the assembly continues to spin until the epoxy
partially cures. Then the excess epoxy and casting pots 312 are cut
away at both ends leaving open hollow fiber holes at both ends of
the assembly, and the next epoxy potting step is performed. To
insure that leaks do not occur between manifolds, the manifolds 208
are welded or epoxied along their borders.
[0117] FIG. 4 is an illustration describing the four main steps of
both procedures for assembly of one module of the instant invention
which is composed of three sets of fibers. The procedure is, first
step 401 insert the outer fiber 110 ends into holes in first
manifolds 302, then attach first manifold 302 to housing 202, and
pot fiber ends. The next step 402 is insert second set of fibers,
or middle fibers 106, into outer fiber 110, insert fiber ends in
holes in the second manifolds 304, and pot fiber ends. The next
step 403 is insert inner fibers 102 into middle fibers 106 and
insert fiber ends into holes on the third manifolds 306 and pot
fiber ends. The last step 404 is attach endcaps. At least two
dowels are inserted into adjacent manifolds during the second 402
and third 403 steps by way of dowel holes 310 to align holes in
adjacent manifolds. The second manifold 304 has four dowel holes
310 because at least 2 are filled with a hollow fiber that
maintains dowel hole void 310 after potting process is complete so
dowel can be inserted and second manifold 304 can be aligned
properly with third manifold 306. Thermoplastic welding can be
performed on similar materials, therefore, in the instant invention
the first manifold 302 is made of polypropylene in order to weld
polypropylene fibers.
[0118] FIG. 5 illustrates the general process of welding. A Teflon
cork 501 is inserted in the inner diameter of the hollow fiber 502
forcing the fiber walls against the wall of the holes 503 in the
manifold 208. A heat gun, or thermoplastic welder 504 is used to
melt the fiber wall 502 and wall of the holes 503 together. Once
the assembly is cooled the teflon plug is removed. A jib of teflon
plugs that match the first manifold 302 holes is used to weld the
outer fibers ends to the respective first manifolds 302. Both ends
of the housing 313 have a slot into which first manifold 302 fits.
A similar jib of teflon plugs fitting the second manifold 304 and
third manifold 306 can be used to thermoplastically weld all three
sets of fibers if fibers are composed of same material as manifold,
and most likely will result in non-centered coaxial fibers. In the
first step 401, first manifold 302 is welded to housing 313. In
second step 402, second manifold 304 is welded to manifold 302. In
third step 403, third manifold 306 is welded to second manifold
304. In fourth step 404, endcaps 210 are welded to third manifold
306.
[0119] FIG. 6A illustrates a two-sided multi-coaxial hollow fiber
bioreactor. The bioreactor is assembled using parts machined or
formed from polypropylene or any other machined or formed material
using two of each part, one for each respective end of the
bioreactor, three semi-permeable hollow fibers, and an
approximately eight to ten millimeter diameter nuclear magnetic
resonance (NMR) tube (available, for example, from Wilmad Inc.,
Buena, N.J.). The hollow fibers used to construct the bioreactor
are approximately 8 millimeters o.d. with wall thickness of 0.5
millimeters, 2.6 millimeters o.d. with wall thickness of 0.4
millimeters, and 0.8 millimeters o.d. with wall thickness of 0.2
millimeters and made of polypropylene with 0.2 micrometer pore size
(available, for example from Akzo-Nobel, Germany). The respective
fibers can be composed of a 8 millimeter o.d. silicone tube
(available, for example, from Dow Corning, Midland, Mich.), and 3
and 1.3 millimeter o.d. polysulfone hollow fibers (available, for
example, from AG/Technologies, Inc., Wilmington, Del.) with 0.4 and
0.2 millimeter wall thickness, respectively, and with 0.1 and 0.65
micrometer pore sizes, respectively. Alternatively, a smaller o.d.
and thinner walled silicone tube can be used for the outer fiber
110 and pulled over a perforated rigid tube to give structural
rigidity. Diffusion of oxygen is inversely proportional to the wall
thickness, and therefore, the thinner walled silicone tubing will
permit superior mass transfer of oxygen. The 2.6 millimeters o.d.
polypropylene fiber can be replaced and constructed with a 3
millimeters o.d. polysulfone fiber with a wall thickness of 0.5
millimeters and with 0.65 micrometer pore size. These fibers can
consist of any desired hollow fiber or tube with appropriate
changes in the design specification of the respective parts to fit
the respective fiber.
[0120] Fibers are cut to be at least 2 millimeters longer than
their final length when assembled.
[0121] The outer fiber 110 can be coated with a perfluorinated
polymer to bridge or clog the pores to avoid `wetting`, or
saturation with water, or pores and effectively eliminating
evaporation of water from media using a process provided by Compact
Membrane Systems (Wilmington, Del.) or other similar pore-filling
process. Coating could also be performed on the scaled-up
multicoaxial bioreactor described in FIG. 3. For mass transfer
purposes, the coating occurs on the media sided of the fiber. If
coating is not performed the air compartment must have higher
pressure than adjacent media compartment to avoid pore wetting, and
the gas stream should be warmer than media stream to decrease
evaporation and condensation.
[0122] In the instant invention, the two-sided multi-coaxial
bioreactor is assembled with largest outer fiber 110 (e.g., 5
millimeters i.d., 8.1 millimeters o.d.) and first manifold 302.
Securing means such as polyurethane epoxy or thermoplastic welding
or combination thereof are used to fix the fibers to the respective
parts. Housing, an NMR tube 604, is secured to first manifolds 302
by collars 606 and O-rings 602.
[0123] FIGS. 6B, 6C and 6D further illustrate the first manifold.
As shown in FIG. 6B, the front side comprises first circular
recessed area 610 while as shown in FIG. 6C the back side comprises
first circular raised area 612. Both first circular recessed area
610 and first circular raised area 612 partially define first void
614. As shown in FIG. 6D, O-ring 602 is placed into first circular
recessed area 610. Collar 606 is attached thereto. Outermost port
218 is also shown.
[0124] FIGS. 6E, 6F, 6G and 6H further illustrate the second
manifold. As shown in FIG. 6F, the front side comprises second
circular recessed area 620 while, as shown in FIG. 6G, the back
side comprises second circular raised area 622. Both second
circular recessed area 620 and second circular raised area 622
partially define second void 624. In order to insure that cells do
not collect in the space between second manifold 302 and third
manifold 304, a collar 326 can be slipped over the middle fiber 106
and snuggly fitting into the second void 624 and into the front
void 636 of third manifold 304. Second middle port 216 is also
shown. FIG. 6C also illustrates the fashion in which first manifold
302 communicates with second manifold 304.
[0125] FIG. 6I provides a perspective view of the second manifold,
illustrating second void 624, second middle port 216, and first
middle port 214.
[0126] FIG. 6J, 6K and 6L further illustrate the third manifold. As
shown in FIGS. 6J and 6K, the front side comprises third circular
recessed area 630 that partially defines third void 634. First
middle port 214 is also shown in FIG. 6L. FIG. 6M also illustrates
a cross section of the complete assembly, showing how second
manifold 304 communicates with third manifold 306.
[0127] FIG. 6N is a top view of the complete assembly of a two
sided bioreactor with all four inlet and outlet ports on one side
of the manifold, illustrating first manifold 302, second manifold
304, third manifold 306, media port 212, cell port 214, media port
216, gas port 218 and collar 606.
[0128] The bioreactor can be mass produced using stand or holder
702 illustrated in FIG. 7. The stand holds the manifold 208 and
fiber axis 703 in a groove 701 so that the axis of the fiber 703 is
90 degrees perpendicular to the plane of the manifold 704
containing the fiber hole opening 705. Then the fibers are fixed by
filling the manifold/fiber space 706 with epoxy, or a thermoplastic
welding process as depicted in FIG. 5. If epoxy is used then the
epoxy is rapidly cured in an oven and then the other side is potted
and the entire procedure depicted in FIG. 7 is repeated. The
manufacture can be automated for mass production where the process
of bioreactor assembly shown in FIG. 4 is performed robotically. In
a mass produced two-sided bioreactor, the O-rings 602 and collars
610, and threads on first manifold 302 which are used to make a
seal with the 10 mm glass NMR tube 604 are replaced by using a tube
composed of polypropylene or appropriate material to replace the
glass 10 mm NMR tube 604 and are thermoplastically welded or
epoxied to create a seal. In a preferred embodiment the outer fiber
110 is welded and the two inner fibers 102 and 106 are epoxied.
With respect to the coaxial fibers, the fiber manifold 208
assemblies (FIG. 6) are attached radially from the largest to
smallest diameter fibers, and axially from the smallest to largest
diameter fibers. The outer fiber 110 is inserted into O-rings 602,
2 collars 606, a 10 mm NMR tube 604, and then into the first
manifold 302. The two collars are tightened, and then first
manifolds 302 at both ends of the bioreactor assembly are inserted
into the grooves 701 of the stand 702. The outer fibers 110 are
thermoplastically welded in place using, for example, the process
described in FIG. 5. The bioreactor now assuming a dumbbell shape
is ready for attaching the second manifold 304.
[0129] A second fiber of about 2.6 millimeter o.d. polypropylene or
3 millimeter o.d. polysulfone is inserted into the outer fiber of
dimension 5 mm o.d. and affixed to second manifold 304 by the epoxy
process depicted in FIG. 7. First manifold 302 and second manifold
304 are welded along their borders. A third fiber of 0.8 millimeter
o.d. is inserted into the second fiber of 1.8 millimeter i.d.
polypropylene or 2 millimeter i.d. polysulfone hollow fibers and is
affixed to third manifold 306 as described above. During attachment
of fibers to the manifold on only the second end of the bioreactor,
the fibers are cut flush with their respective manifolds or part
numbers. Endcap 210, or threaded hose bard, is glued to, or screwed
onto third manifold 306 at each end.
[0130] FIG. 8 discloses a coaxial bioreactor with inlet port 802
and outlet ports 804 on one side of the bioreactor. In a preferred
embodiment, this bioreactor is axially less than 40 millimeters
long and the fibers are secured with manifolds or endcaps that have
coaxial counter-sunk holes that fit the fiber diameters within
.+-.5 mils of an inch. Optionally, hepatocytes center the inner
fiber, thereby making construction easier and permitting axial
scale-up. The bioreactor can be partially filled depending on
inoculation procedure. The bioreactor is assembled with an inner
fiber 102, middle fiber 106, outer fiber 110, and manifolds 208 in
a fashion similar to the two-sided multi-coaxial hollow fiber
bioreactor, except there is only one inlet and one outlet. The one
sided multi-coaxial bioreactor of FIG. 8 uses the same fibers and
NMR tube described above for the two-sided multi-coaxial hollow
fiber bioreactor. In this embodiment housing 114 is an NMR tube.
The specific design can be inserted in an 10 millimeter NMR probe
used with conventional vertical bore magnets. Flow direction 806
can be switched by swapping inlet port 802 and outlet ports 804.
The flow rate in the outer annulus is partly controlled by the
diameter and number of holes 808 aligned as a circle around the
three manifolds. The manifolds and fibers are assembled as
described above for the two-sided single multi-coaxial hollow fiber
bioreactor. Also shown is inoculation port 810 and air flow
812.
[0131] An additional one-sided multi-coaxial hollow fiber
bioreactor design can be constructed by dead-ending the inner fiber
102 and omitting the holes 808 in the bottom manifold 812. This
changes the flow configuration by forcing the flow path from inner
compartment 104 through the first middle compartment 108 where
cells reside and exiting through the second middle compartment 112,
or vice versa. Since oxygenation occurs in the outer compartment in
the instant invention, it is preferred to flow from second middle
compartment 112 toward the inner compartment 104 so that media
becomes appropriately oxygenated before entering the cell mass.
[0132] To enhance NMR sensitivity the one-sided bioreactor can be
made to fit inside a smaller diameter NMR tube such as 8 to 15 mm.
In order to achieve a smaller diameter, in one embodiment of the
instant invention a 200 .mu.m to 500 .mu.m o.d. microbore aeration
fiber serves as inner fiber 102, a 1 to 1.3 millimeter o.d., middle
fiber 106, and a 3 to 4 millimeter o.d. outer fiber 110. With
oxygenation occurring by way of the inner compartment 104 the
preferred flow is from the first middle compartment 108, through
cell mass in the second middle compartment 112, and exiting by way
of the outer compartment 116. The gas chamber, of inner compartment
104, is dead-ended, and gas is flushed from the compartments by way
of diffusion to a flowing air stream connected to the gas chamber
by way of a tee connectors at the top of the bioreactor. In order
to have air circulate through the bioreactor, an air flow-through
the design is needed. The inner fiber 102 in FIG. 9 is manifolded
at the bottom of the bioreactor and at least one 200 .mu.m to 500
.mu.m return microbore aeration fiber 902 is epoxied into holes 808
in the manifolds bordering the outer compartment 116 and used for
media return. Alternatively, a two-fiber coaxial bioreactor is
constructed from an inner fiber mini-oxygenator composed of 0.8 mm
polypropylene fibers is placed in-line to the one-sided bioreactor
and gas is heated by water-jackets to avoid outgasing due to
temperature changes and/or differences between oxygenation device
and bioreactor.
[0133] FIG. 10A illustrates the serially-linked bioartificial
liver. It includes at least two bioartificial liver subunits with
potentially up to about 160 g of tissue per subunit. Cell
suspensions are introduced into the respective annular compartments
by way of ports 1006 and/or 1014 and 1024 and/or 1032, and allowed
to anchor to the annular compartments. Radial flow dynamics are
used to perfuse media from plasma to cells for biotransformatory
functions. The flow scheme is switched in the second subunit so
synthetic factors can flow from the cells back into the plasma.
Radial flow is discussed further, infra.
[0134] As shown in FIG. 10A, plasma 1001 from the patient enters
first bioartificial liver subunit 1002 through first plasma
entrance port 1004, media enters 1054 first bioartificial liver
subunit 1002 through first media entrance port 1008 and gas enters
first bioartificial liver subunit 1002 through first gas entrance
port 1010. Radial flow is produced by selecting hollow fibers with
characteristics of pore size and pore number such that the
hydraulic permeability of the fiber is relatively high and by
having a substantial pressure gradient across the fibers as
determined in the hydrodynamic model discussed below. FIG. 10B
depicts plasma flow under conditions where plasma compartment 1042
has higher pressure than cell compartment 1044 and media
compartment 1046. Under these conditions, some plasma flows
radially from entrance port 1004 to plasma compartment 1042,
through cell mass contained in cell compartment 1044, into media
compartment 1046, and out the media exit port 1016. The remaining
plasma then exits first bioartificial liver subunit 1002 through
first plasma exit port 1012, and the plasma is divided by
tee-junction 1048. Media exits first bioartificial liver subunit
1002 through first media exit port 1016 and gas exits first
bioartificial liver subunit 1002 through first gas exit port 1018.
The elevated pressure in plasma compartment 1042 necessary to
create the .DELTA.P to drive radial flow is created by dividing the
plasma stream at tee junction 1048 and rapidly recirculating plasma
through plasma compartment 1042 by way of recirculating pump 1013
connecting the plasma entrance port 1004 to plasma exit port 1012.
The flow rates or velocities create sufficient head pressure at the
plasma entrance port 1004 and pump rates are adjusted for desired
.DELTA.P which is measured by pressure gauges 1048 at ports 1004
and 1008. The desired .DELTA.P can also be created by insertion of
a needle valve 1054 in the line between the plasma exit port 1012
and the tee junction 1048. In this manner, plasma flow rate can
remain constant through the first bioartificial liver subunit 1002
and the desired .DELTA.P is achieved by modulating flow through the
needle valve. The same principle can used to control radial flow in
the second bioartificial liver subunit 1020. In an alternative
embodiment, plasma compartment 1042 is dead-ended by eliminating
plasma exit port 1012.
[0135] The flow scheme is then switched in the second subunit such
that the fluid from exit port 1016 enters second bioartificial
liver subunit 1020 through second media entrance port 1022, plasma
enters second bioartificial liver subunit 1020 through second
plasma entrance port 1026 and gas enters second bioartificial liver
subunit 1020 through second gas entrance port 1028. A portion of
the media flows radially from the entrance port 1022 through the
annular cell layer and into the plasma component. The remaining
media then exits second bioartificial liver subunit 1020 through
second media exit port 1030 and the fluid stream is split at tee
junction 1050 and a portion is returned to the patient 1052. Cells
optionally exit second bioartificial liver subunit 1020 through
second cell exit port 1032, plasma exits second bioartificial liver
subunit 1020 through second plasma exit port 1034 and gas exits
second bioartificial liver subunit 1002 through second gas exit
port 1036. FIG. 10C depicts plasma-containing media flow where the
media compartment 1046 is now switched with the plasma compartment
1042. As described above, the .DELTA.P is established in the media
compartment 1046 by rapid recirculation of the plasma-containing
media by pump 1031 to create sufficient head pressure. The .DELTA.P
is measured by pressure gauges 1049 at ports 1022 and 1026. In an
alternative embodiment, sufficient head pressure is created by
eliminating or restricting (using a needle valve or other similar
device) the flow through the second media exit port 1030.
[0136] In order to create radial flow, several flow configurations
are possible. Flow rate differences in two compartments results in
a pressure difference (.DELTA.P) creating radial flow across the
annular space, which is governed by Darcy's law: v.sub..tau.=k
.DELTA.P/.eta.L (I) where v.sub..tau. is the radial flow velocity,
k is the hydraulic permeability, a constant dependent on the
physical features of the hollow fiber (including pore size and pore
number), the solvent, and the solute, .eta. is the viscosity of the
solution, and L is the length of the contact between the two
compartments, here, essentially the fiber length. Any of a variety
of pore sizes can be selected, including, but not limited to
10.sup.-6 m, 0.1.times.10.sup.-6 m, and 0.05.times.10.sup.-6 m.
Thus radial flow can be enhanced by a suitable choice of fibers
with a high hydraulic permeability and by modulation of flow
rates.
[0137] A model based on Darcy's law permits one to estimate the
correlation between pressure difference and radial flow given the
hydraulic permeabilities of the inner fiber 102 and middle fiber
106. The model assumes incompressible and Newtonian fluid, and that
the axial pressure gradient is negligible, and the flow rate across
the fibers was constant. Deriving this equation for two concentric
hollow fibers the following relationship is obtained. .DELTA.
.times. .times. P = Q 2 .times. .pi. .times. .times. L [ ln
.function. ( r b r a ) K 1 - ln .function. ( r d r c ) K 2 ] ( II )
##EQU1##
[0138] FIG. 11A defines the variables used in the equation. Q is
radial flow rate from compartment 1102 characterized by a
hydrostatic pressure P.sub.1, through pores in fiber 1104
characterized by hydraulic permeability K.sub.1, through
intermediate compartment 1106, then through pores in second fiber
1108 characterized by hydraulic permeability K.sub.2 to compartment
1110 characterized by hydrostatic pressure P.sub.2. The radial
distances from a centerline to the inside of fiber 1104 is r.sub.a,
to the outside fiber 1104 is r.sub.b, to the inside fiber 1108 is
r.sub.c and to the outside of fiber 1108 is r.sub.d. It is to be
understood that the direction of radial flow of any particular
chemical constituent, including but not limited to oxygen, culture
medium, plasma, and biosynthetic products, depends on the direction
of the pressure differential. The directions of flow and of the
corresponding radial flow rate can be either positive or negative,
and are represented by the sign of the flow and of Q. The invention
contemplates values of Q corresponding to flow from inner
compartments to outer compartments, and equally contemplates values
of Q corresponding to flow from outer compartments to inner
compartments. FIG. 11B compares the experimental data of radial
flow from the second middle compartment 112 to the inner
compartment 104 as a function of pressure difference to the modeled
data using experimentally determined values of K.sub.1 and K.sub.2.
FIG. 11C illustrates the pressure in the cell compartment 1106
corresponding to the experiment shown in FIG. 11B. Comparison of
FIG. 11B to 11C shows that the majority of transmembrane pressure
difference occurs across the middle fiber 106 and this is because
of the relatively large hydraulic permeability and wall thickness
of the middle fiber 106. Therefore, cells are protected from the
adverse effects of high pressure created in the second middle
compartment 112, and as the hydraulic permeability of the middle
fiber 106 increases, the pressure is more easily transmitted to the
first middle compartment 108 and cells becomes less protected from
the pressure in the second middle compartment 112. Therefore, this
model can be generally used in the operation of the bioreactor to
predict the appropriate pressure difference for given inner 102 and
middle 106 fibers hydraulic permeabilities. In preferred
embodiment, the device includes a software program based on this
predictive model which aids in the selection of culture conditions
regarding radial flow velocities and hydrostatic pressures in the
cell compartment.
[0139] A method of selecting a radial flow rate in a bioreactor
comprising semi-permeable fibers to enhance cell viability
comprising: measuring a first hydraulic pressure associated with a
first semi-permeable fiber and a second hydraulic pressure
associated with a second semi-permeable fiber to obtain a pressure
differential and adjusting the first hydraulic pressure, the second
hydraulic pressure, or a combination thereof to select one or more
radial flow rates so as to improve cell viability.
[0140] Thus, in one embodiment, the invention comprises a method of
selecting a radial flow rate in a bioreactor comprising
semi-permeable fibers to enhance cell viability comprising:
measuring a first hydraulic pressure associated with a first
semi-permeable fiber and a second hydraulic pressure associated
with a second semi-permeable fiber to obtain a pressure
differential and adjusting the first hydraulic pressure, the second
hydraulic pressure, or a combination thereof to select one or more
radial flow rates so as to improve cell viability. The first fiber
and the second fiber can be coaxial. In a particular embodiment,
the method of selecting a radial flow rate comprises selecting the
radial flow rate based on the formula: .DELTA. .times. .times. P =
Q 2 .times. .pi. .times. .times. L [ ln .function. ( r b r a ) K 1
- ln .function. ( r d r c ) K 2 ] ##EQU2## where .DELTA.P is the
pressure differential, Q is the radial flow rate, L is the length
of the shorter of the first and second fiber lengths, r.sub.a is
the radial distance from the centerline of the bioreactor to the
inner surface of the first fiber, r.sub.b is the radial distance
from the centerline of the bioreactor to the outer surface of the
first fiber, r.sub.c is the radial distance from the centerline of
the bioreactor to the inner surface of the second fiber, r.sub.d is
the radial distance from the centerline of the bioreactor to the
outer surface of the second fiber, K.sub.1 is the hydraulic
permeability of the first fiber, and K.sub.2 is the hydraulic
permeability of the second fiber.
[0141] The software can be in the form of an algorithm as
illustrated in FIG. 12, and used to select mass transfer conditions
for specific cell types. Initial .DELTA.P values are obtained from
a knowledge of characteristics of the bioreactor, including
diffusion distance 118 and fiber length, as well as known
physiological conditions in the tissue of interest.
[0142] A detailed description of the radial flow algorithm is
provided in FIG. 12. The first step shown in block S20 begins with
input of parameters of the bioreactor, including the geometry and
dimensions of the bioreactor, and parameters of the cells,
including resistance to hydrostatic pressures and shear stress. The
pressure differential is then sampled, block S22. The next step
requires a determination of whether the pressure differential is
within the limits of hydrostatic pressure consistent with continued
viability of the cells used in the system, as shown in block S24.
If the pressure differential is not within permissible limits, the
pressure differential is adjusted, as shown in block S26. Then the
hydrostatic pressure is again measured to determine if it is within
permissible limits, as shown in block S28.
[0143] If the determination from either block S24 or block S28 is
that the hydrostatic pressure is compatible with cell viability,
then the radial flow is measured, as shown in block S30.
[0144] The next step requires a determination of whether the shear
forces associated with radial flow are within viability limits for
the cell type of interest, as shown in block S32. If the shear
forces are not within permissible limits, the formula II, supra,
relating .DELTA.P and the radial flow rate Q is applied, as
illustrated in block S34. As a result of the calculation of block
S34, more suitable hydraulic permeability K.sub.1 and/or hydraulic
permeability K.sub.2 is determined, as necessary S36.
[0145] Upon change in one or more hydraulic permeabilities, as in
block S34, the system returns to block S24 for further evaluation
of first hydrostatic pressure and then shear force.
[0146] When the hydrostatic pressure is within limits consistent
with cell viability, as in either block S24 or block S28, then the
radial flow rate, Q, is measured as in block S30. If the shear
forces associated with the radial flow is consistent with cell
viability, then conditions for cell survival are established, as
illustrated in block S38. By setting suitably narrow limits for
permissible hydrostatic pressure and shear force, an optimum
condition for prolonged cell survival is attained.
[0147] In another embodiment, the invention can comprise a computer
readable medium including instructions therein for calculating a
radial flow rate in a bioreactor comprising semi-permeable fibers,
said instructions including the steps of: (a) receiving
measurements of hydraulic permeability for each of at least two
semi-permeable fibers, (b) receiving hydraulic pressure
measurements associated with a pressure differential for at least
two coaxial semi-permeable fibers, and (c) estimating said radial
flow rate between said coaxial semi-permeable fibers.
[0148] FIG. 13A illustrates a cross section of a multi-coaxial
bioreactor comprising three coaxial hollow fibers nested within
each other. FIG. 13A depicts innermost fiber 102, middle fiber 106,
outer fiber 110 and housing 114.
[0149] FIG. 13B illustrates a cross section of an alternative
embodiment of a multi-coaxial bioreactor. FIG. 13B depicts
innermost fiber 102 middle fiber 106, smaller aeration fiber 1302
and housing 114. Smaller standard aeration fiber 1302 is placed in
the spaces formed by stacking coaxial fibers which comprise
innermost fiber 102 and middle fiber 106. Thus, a first compartment
is formed by the inner wall of innermost fiber 102. A second
compartment is defined by the outer wall of innermost fiber 102 and
the inner wall of middle fiber 106. A third compartment is defined
by the outer wall of middle fiber 106 and housing 114. A fourth
compartment is formed by the inner wall of smaller aeration fibers
1302. In alternative embodiments, a fifth compartment can be
created for aeration purposes by inserting a fourth, small aeration
fiber inside innermost fiber 102.
[0150] FIG. 14 illustrates an embodiment of a bioreactor. The
following components are shown: first manifold 302, second manifold
304, endcap 210, inner compartment inlet 1408, inner compartment
outlet 1410, cell compartment 1412, gas inlet 1414, gas outlet
1416, outermost compartment inlet 1418, outermost compartment
outlet 1420 and housing 202.
[0151] FIG. 15 illustrates a device used in the construction of a
bioreactor. Components shown include plurality of fibers 1502,
second manifold 304, first manifold 302, housing 202, O-ring 416,
vacuum head 1504, and mesh 1506. The vacuum allows for rapid
insertion of smaller fibers into larger fibers. Mesh 1506 retains
the fibers in place.
[0152] In scaled-up versions of the multi-coaxial bioreactor,
manifolds consist of multiple coaxial holes for the various fibers,
and dowels are placed in holes precisely located on the manifolds
to insure that all multi-fiber units are coaxial. Since multi-fiber
units are reproduced accurately due to the coaxial design,
experimental parameters from a single multi-fiber unit are directly
applied to the scaled-up bioreactor.
[0153] The construction of the bioreactor may have many variations
that will be evident to the practitioner. As one example, the
hollow fibers may vary in pore size, length, wall thickness and
composition and the hydrodynamic model shown above and in FIG. 11
can be used to determine the optimum hollow fiber characteristics.
The hollow fibers may be made of any of a number of materials
including, but by no means limited to polysulfone, cellulose
acetate, mixed esters of cellulose, regenerated cellulose,
polyvinylalcohol, polyurethane, polyvinylidine, polypropylene,
polycarbonate, and polyamide. Cellulose acetate is more permeable
to nutrient media and polypropylene is more permeable to gases and
those skilled in the art will select appropriate fibers based on
these and other properties. The means of formation of pores and
control of the pore size will be obvious to one of skill in the art
and may include, but in no way be limited to, neutron bombardment,
controlled polymerization, and incorporation of leachable agents.
Any of several adhesives including polyurethane epoxy may be used
for potting the fibers, and those skilled in the art will know of
appropriate adhesives.
6. EXAMPLES
[0154] The following specific examples are provided to better
assist the reader in the various aspects of practicing the present
invention. As these specific examples are merely illustrative,
nothing in the following descriptions should be construed as
limiting the invention in any way. Such limitations are, or course,
defined solely by the accompanying claims.
[0155] 6.1 NMR Analysis of Liver Cell Function in the One-Sided
Multi-Coaxial Hollow Fiber Bioreactor.
[0156] Sprague-Dawley rats are anesthetized with pentobarbital (50
mg/kg intraperitoneally). The liver is exposed by a ventral midline
incision and the portal vein is cannulated for infusion of cell
dissociation solutions. The liver cells are dissociated by
sequential infusions of ethylene diamine tetraacetic acid (50 mM)
and collagenase (1 to 20 mg/ml) in Krebs-Henseleit buffer, pH 7.4.
Adequate perfusion of the liver is indicated by uniform blanching
of the liver. Isolated cells are collected and introduced into the
cell compartment (compartment 2) of the one-sided multi-coaxial
hollow fiber bioreactor.
[0157] Nuclear magnetic resonance (NMR) is performed using an NMR
probe design composed of two Helmholtz coils photo-etched onto
flexible copper-coated composite. The two coils, suitably
insulated, are wrapped around the bioreactor and oriented
orthogonally to each other. The inner coil is tuned to 81 MHz for
study of energy metabolism as measured by changes in the spectrum
of .sup.31P. The probe and bioreactor assembly is placed on a
centering cradle in the isocenter of the magnet for optimal
comparison of spectra. The aerated nutrient medium is supplied to
the first compartment inlet port of the bioreactor. Integral
aeration is provided by flow of a 95% air with 5% CO.sub.2 mix
through inlet port 4, associated with the outermost or fourth
compartment of the bioreactor. Ham's F-12 nutrient medium is pumped
through compartment 3 with a peristaltic pump. The temperature of
the reservoir of medium is maintained at 42.degree. C. with a
temperature controlled water bath, so as to maintain the bioreactor
temperature at 37.degree. C. The NMR signal from .gamma.-.sup.31P
nucleotide triphosphates and .beta.-.sup.31P nucleotide
diphosphates, other cellular components of energy metabolism, and
biosynthesis are analyzed. The NMR signal is monitored as a
function of mass transfer dictated by gas flow rate and oxygen
percentage, nutrient medium flow rates, and cell loading
densities.
[0158] 6.2 Oxygen Flux in the Absence of Cells.
[0159] Oxygen microelectrodes are connected to a transducer and
Workbench.TM. software, and then calibrated against known
standards. The calibrated oxygen microelectrodes are placed at
intervals along the fiber length in compartment 2 of the multi
coaxial hollow fiber bioreactor. A reservoir of plasma is attached
to the inlet port of compartment 1, the innermost compartment of
the multi-coaxial hollow fiber bioreactor. A reservoir of RPMI 1640
nutrient medium is attached to the inlet port of compartment 3.
Peristaltic pumps are arranged in-line to circulate the plasma and
nutrient medium. Compartment 2 is also filled with nutrient medium.
The signal from each microelectrode is acquired at ten-second
intervals and processed by the software for conversion to oxygen
tensions. The gas phase is switched between 95% air with 5%
CO.sub.2 and 95% N.sub.2 with 5% CO.sub.2 at selected intervals.
Rates of depletion and recovery of oxygen tension are measured at
different flow rates to evaluate oxygen flux in the absence and
presence of cells.
[0160] 6.3 Use As An Extracorporeal Liver Assist Device for
Evaluation of Bilirubin.
[0161] Background. The Gunn rat model, which is the animal model
for Crigler-Naijar syndrome in humans is an ideal model for
demonstrating the efficacy of the bioreactor as an extracorporeal
liver assist device. The Gunn rat has a defect inherited as an
autosomal recessive trait in Wistar rats. The defect, present in
homozygous recessive animals, is in the gene encoding
UDP-glucuronosyltransferase, an enzyme necessary for the
conjugation and biliary excretion of bilirubin (a breakdown product
of hemoglobin in senescent red blood cells). The Gunn rat therefore
cannot conjugate and excrete bilirubin and becomes
hyperbilirubinemic, having serum bilirubin levels of about 5-20
mg/dL, compared with 1 mg/dL in normal rats.
[0162] Experimental Protocol. A scaled-up multi-coaxial hollow
fiber bioreactor is used as an extracorporeal liver assist device
with Gunn rats. The livers of heterozygous (phenotypically normal)
Gunn rats are perfused and the cells are isolated. The cells are
suspended in Dulbecco's Modified Eagle Medium (DMEM) and 10.sup.9
cells are introduced into the second compartment of the bioreactor.
Blood from the femoral artery of a Gunn rat (total average blood
volume ca. 10 to 12 mL) is perfused through compartment 3 of the
bioreactor, separated from the liver cell annular space by the wall
of the hollow fiber, at a flow rate of about 0.6-0.8 mL/min with
the aid of a peristaltic pump. At the same time, DMEM is flowed
through the compartment one of the bioreactor at a flow rate of
about 0.5 mL/min. Blood flowing out of the bioreactor is returned
to the Gunn rat.
[0163] The levels of unconjugated and conjugated bilirubin in blood
exiting the bioreactor are determined over the course of six hours
using the Sigma Total and Direct Bilirubin assay system according
to the instruction supplied by Sigma Chemical Company (Sigma
Procedure #522/553).
[0164] 6.4 Biosynthetic Hepatocyte Function in a Scaled-Up
Multi-Coaxial Hollow Fiber Bioreactor/BAL.
[0165] Liver cells isolated as in Example I are further separated
by zonal centrifugation in sucrose density gradients. Density
fractions corresponding to parenchymal cells are collected and
introduced into the aseptic cell compartment (compartment 2) of the
scaled-up multi-coaxial bioreactor.
[0166] The parenchymal cells are maintained by circulating warm
Ham's F-12 nutrient medium through compartments 1 and 3, and 95%
air with 5% CO.sub.2 through compartment 4. The effluent from
compartment 1 is collected and fractions are analyzed for
parameters of biosynthetic liver function. Albumin synthesis is
measured by enzyme-linked immunosorbent assay.
[0167] 6.5 Biotransformatory Function in a Scaled-Up Multi-Coaxial
Hollow Fiber Bioreactor/BAL.
[0168] Liver cells isolated as in Example I are further separated
by zonal centrifugation in sucrose density gradients. Density
fractions corresponding to Kupffer cells are collected and
introduced into the compartment 2 (cell compartment) of the
scaled-up multi-coaxial hollow fiber bioreactor.
[0169] The cells in the bioreactor are maintained by circulating
DMEM (without Phenol Red) through the inlet and outlet ports for
compartments 1 and 3 and 95% air with 5% CO.sub.2 through the ports
for compartment 4. The cells are permitted to adhere within the
compartment, followed by the introduction of free hemoglobin (1-10
mg/ml) into compartment 1. The appearance of hemoglobin and the
metabolic products of hemoglobin in compartment 3 are monitored
with an in-line spectrophotometer.
[0170] 6.6 The Serially-Linked Bioreactor with Human Cells for
Patient Treatment.
[0171] Human hepatoma C3A cells are cultured as described
(Mickelson, J. K. et al. Hepatology 1995, 22, 866) and introduced
into all the second compartments of the serially-linked bioreactor.
Nutrient medium and 95% air with 5% CO.sub.2 are pumped through the
third and outermost compartments, respectively, and cell growth is
monitored by glucose utilization. When the cells have attained the
plateau, or stationary, growth phase, the albumin output is
monitored.
[0172] The blood of a patient suffering liver failure is separated
into plasma and cells by plasmapheresis and the plasma is pumped
into the first compartment of the first bioartificial liver
subunit. A portion of the plasma flows radially from the first
compartment through the cell compartment to the third compartment
to form biotransformed effluent. The plasma exits the first
compartment of the first bioartificial liver subunit and flows into
the third compartment of the second bioartificial liver subunit.
The biotransformed effluent from the third compartment of the first
bioartificial liver subunit flows into the first compartment of the
second bioartificial subunit. Radial flow in the first
bioartificial liver subunit detoxifies a portion of the plasma and
radial flow in the second bioartificial liver subunit contributes
biosynthetic products to the plasma to form supplemented plasma.
Vital signs, jaundice, and blood level of toxins are monitored at
regular intervals. Flow rates of plasma and medium are adjusted to
maximize biotransformation of circulating toxins. Survival of the
patient is measured.
[0173] 6.7 Extracellular Matrix Effects on Differentiation of
Hepatocytes in the Scaled-Up Multi-Coaxial Hollow Fiber
Bioreactor.
[0174] Parenchymal cells are isolated by zonal centrifugation as in
example IV, above, suspended in reconstituted basement matrix from
the Englebreth-Holm-Swarm mouse sarcoma, and introduced into the
compartment 2 (cell compartment) of the scaled-up multi-coaxial
bioreactor. The hepatocytes are arrested in a G.sub.0 state by
adhesion to the basement matrix, and are maintained in the normal
hepatic phenotype (Rana et al., 1994). The highly differentiated
state is characterized by synthesis of albumin and hepatic
transcription factors such as C/EBP-. The parenchymal cells are
maintained by circulating warm Ham's F-12 nutrient medium through
compartments 1 and 3, and 95% air with 5% CO.sub.2 through
compartment 4. The effluent from compartment 1 is collected and
fractions are analyzed for parameters of biosynthetic liver
function. Albumin synthesis is measured by enzyme-linked
immunosorbent assay.
[0175] 6.8 Growth and Differentiation of Human Hepatocytes in the
Scaled-Up Multi-Coaxial Hollow Fiber Bioreactor.
[0176] Human parenchymal hepatocytes are isolated by the method of
(Block, G. D. et al. J Cell Biol 1996, 132, 1133) and introduced
into compartment 2 of the scaled-up multi coaxial hollow fiber
bioreactor. The parenchymal cells are propagated by exposure to
hepatocyte growth factor (HGF/SF), epidermal factor, and
transforming growth factor alpha in nutrient medium HGM introduced
into compartment 3 and air:CO.sub.2 (19:1) introduced into
compartment 4. The ratio of transcription factor C/EBP to C/EBP is
decreased by this process and the cell synthesis of albumin also is
decreased. The medium flowing through compartment 3 is modified to
include transforming growth factor and epidermal growth factor to
induce differentiation of the cells and synthesis of albumin, in
the formulation described (Sanchez, A. et al. Exp Cell Res 1998,
242, 27).
[0177] 6.9 Biosynthesis of Hormones and Factors in the Scaled-Up
Multi-Coaxial Hollow Fiber Bioreactor.
[0178] Parathyroid glands are obtained aseptically, minced, and
treated with collagenase as described (Hornicek, F. L. et al. Bone
Miner 1988, 4, 157). The dispersed cells are suspended in CMRL-1415
nutrient medium supplemented with fetal bovine serum and introduced
into compartment 2 of the scaled-up multi-coaxial bioreactor. A
mixture of 95% air and with 5% CO.sub.2 is pumped through port 4.
Warm medium is pumped through ports 1 and 3 and the effluent from
the chamber is concentrated by ultrafiltration for collection of
parathyroid hormone, parathyroid hypertensive factor, and other
cell products. The hormones and factors are purified by
immunoprecipitation and chromatography.
[0179] 6.10 The Five Compartment Serially-Linked Bioreactor with
Human Cells for Patient Treatment.
[0180] Human hepatoma C3A cells are grown as in example VI, above,
except in the third compartment of a five-compartment
serially-linked bioreactor. The innermost compartment (compartment
1) and the outermost compartment (compartment 5) are suffused with
the gas mix, 95% air with 5% CO.sub.2. Nutrient medium is pumped
through the second and fourth compartments, respectively, and cell
growth is monitored by glucose utilization. When the cells have
attained the plateau, or stationary, growth phase, the albumin
output is monitored.
[0181] The blood of a patient suffering liver failure is separated
into plasma and cells by plasmapheresis and the plasma is pumped
through the serially connected second compartments of the
bioreactor. Vital signs, jaundice, and blood level of toxins are
monitored at regular intervals. Flow rates of plasma and medium are
adjusted to maximize biotransformation of circulating toxins.
Survival of the patient is measured.
[0182] 6.11 Construction of the Five Compartment Serially-Linked
Bioreactor with Tight-Packed Fiber Arrangement and Use with Human
Cells for Patient Treatment.
[0183] Bioreactor subunits are constructed with 300 outermost
coaxial fibers (3 millimeter o.d.) forming a part of the outer
boundary of the annular cell compartments. A hollow fiber of 1.3
millimeter o.d. is inserted into each of the 3 millimeter fibers,
forming part of the inner boundary of the annular cell compartments
and part of the outer boundary of the compartments number 2. One
micro bore hollow fiber (300 .mu.m o.d.) is inserted into each of
the 1.3 millimeter fibers as the innermost compartment of each
coaxial fiber module and another set of 300 microfibers is placed
parallel and adjacent to the coaxial modules. Both sets of
microfibers carry aeration gas to oxygenate the plasma and the
medium. The outermost compartment is compartment number 4 and is
formed by the outside of the outermost coaxial fibers (of 3
millimeter o.d.), the outside of the microfibers that are adjacent
to the coaxial modules, and the inside of the housing.
[0184] The serially-linked bioreactor and associated tubing and
connections are sterilized.
[0185] Human hepatocytes are isolated as in Example VIII and
introduced into the annular cell compartments, compartments 3, of
each of two bioreactor subunits. The hepatocyte cells are
propagated by exposure to nutrient medium and growth factors
described in Example VIII until the cell density is sufficient for
treatment of a patient in liver failure. The bioreactor subunits
with a complement of viable liver cells are now termed BAL
subunits.
[0186] In use for patient treatment, patient plasma enters
compartment number 2 of the first BAL subunit, through the first
plasma entrance port, media enters compartment number 4 of the
first BAL through the first media entrance port and gas enters the
first BAL through first gas entrance port. Radial flow in the first
subunit is produced by a pressure gradient across the fibers, such
that the hydraulic pressure in the plasma compartment is higher
than the pressure in the cell or media compartments. In
consequence, part of the plasma flows from compartment number 2
through the annular cell compartment into compartment number 4. In
the process the liver cells in the cell compartment can
biologically detoxify the plasma passing through the cell
compartment. As the detoxified plasma flows into compartment 4 the
medium is modified with a detoxified plasma component. The
remaining plasma then exits the first BAL subunit through the first
plasma exit port, media exits the first BAL subunit through the
first compartment number 4 exit port and gas exits the first BAL
subunit through the first gas exit port. The flow scheme is then
switched in the second subunit such that the fluid (medium
containing detoxified plasma) from the first compartment number 4
exit port enters the second BAL subunit through the second
compartment number 2 entrance port. Similarly, plasma from first
compartment 2 exit port enters the second BAL subunit through the
second compartment 4 entrance port and gas enters the second BAL
subunit through the second gas entrance port. A portion of the
media flows radially from the compartment number 2 entrance port
through the annular cell layer and into the second compartment
number 4. The liver cells add proteins and other biosynthetic
products to the medium that flows through the cell compartment in
subunit 2. As this enriched medium flows into the remaining plasma,
the resultant, modified plasma is in part detoxified and in part
enriched with biosynthetic proteins. The remaining medium then
exits the second BAL subunit through the second compartment 2 exit
port, the modified plasma exits the second BAL subunit through the
second compartment 4 exit port and gas exits the second BAL subunit
through the second gas exit port. The modified plasma, effluent
from second compartment 4, is returned to the patient to sustain
life.
[0187] 6.12 Manufacture of Scaled Up Multi-Coaxial Hollow Fiber
Bioreactor.
[0188] An apparatus is used to assemble a bioreactor in which a
vacuum head, that is attached as necessary to a negative pressure
source, holds a bundle of hollow fibers against a mesh for rapid
insertion of smaller fibers. The opposite end of the hollow fibers
is inserted into a manifold and placed in a vessel. Polyurethane
epoxy is applied to bond the hollow fibers to the manifold and the
assembly of manifold, epoxy, and hollow fibers subjected to a
centrifugal force to remove epoxy from the inside of the fibers.
Upon curing, the free ends of the hollow fibers are trimmed with a
saw. The process is repeated for insertion of the next smaller set
of hollow fibers by applying the vacuum, gluing the ends to the
next manifold, centrifuging, and trimming.
[0189] The purpose of the above description and examples is to
illustrate some embodiments of the present invention without
implying any limitation. It will be apparent to those of skill in
the art, in light of this teaching, that various modifications and
variations may be made to the composition and methods in the
present invention to generate additional embodiments without
departing from the spirit or scope of the invention. The specific
composition of the various elements of the bioreactor system, for
example, should not be construed as a limiting factor. Accordingly,
it is to be understood that the drawings and descriptions in this
disclosure are proffered to facilitate comprehension of the
invention and should not be construed to limit the scope
thereof.
[0190] All patents and publications cited herein are incorporated
by reference in their entireties.
[0191] The many features and advantages of the invention are
apparent from the detailed specification, and thus, it is intended
by the appended claims to cover all such features and advantages of
the invention which fall within the true spirit and scope of the
invention. Further, since numerous modifications and variations
will readily occur to those skilled in the art, it is not desired
to limit the invention to the exact construction and operation
illustrated and described, and accordingly, all suitable
modifications and equivalents may be resorted to, falling within
the scope of the invention.
* * * * *